DNA SEQUENCES, RECOMBINANT DNA MOLECULES AND PROCESSES FOR PRODUCING SOLUBLE T4 PROTEINS

Abstract: This invention relates to DNA sequences, recombinant DNA molecules and processes for producing soluble T4 protein. More particularly, this invention relates to DNA sequences that are characterized in that they code on expression in an appropriate unicellular host for soluble forms of T4, the receptor on the surface of T4<+> lymphocytes, or derivatives thereof. In accordance with this invention, the DNA sequences, recombinant DNA molecules and processes of this invention may be employed to produce soluble T4 essentially free of other proteins of human origin. This soluble protein may then advantageously be used in the immunotherapeutic and diagnostic compositions and methods of this invention. The soluble T4-based immunotherapeutic compositions and methods of this invention are useful in treating immunodeficient patients suffering from diseases caused by infective agents whose primary targets are T4<+> lymphocytes. According to a preferred embodiment, this invention relates to soluble T4-based compositions and methods which are useful in preventing, treating or detecting acquired immune deficiency syndrome, AIDS related complex and HIV infection.

Description: DNA SEQUENCES, RECOMBINANT DNA MOLECULES AND PROCESSES FOR PRODUCING SOLUBLE T4 PROTEINS TECHNICAL FIELD OF. INVENTION This invention relates to DNA sequences, recombinant DNA molecules and processes for producing soluble T4 proteins. More particularly, this invention relates to DNA sequences that are characterized in that they code on expression in an appropriate uni¬ cellular host for soluble forms of T4, the receptor on the surface of T4 lymphocytes, or derivatives thereof. In accordance with this invention, the DNA sequences, recombinant DNA molecules and processes of this invention may be employed to produce soluble T4 essentially free of other proteins of human origin. This soluble protein may then advantageously be used in the immunotherapeutic, prophylactic, and diag¬ nostic compositions and methods of this invention. The soluble T4 protein-based immunothera¬ peutic compositions and methods of this invention are useful in treating immunodeficient patients suf¬ fering from diseases caused by infective agents whose primary targets are T4 lymphocytes. According to a preferred embodiment, this invention relates to solu¬ ble T4 protein-based compositions and methods which are useful in preventing, treating or detecting acquired immune deficiency syndrome, AIDS related complex and HIV infection. BACKGROUND ART The class of immune regulatory cells known as T cell lymphocytes can be divided into two broad functional classes, the first class comprising T helper or inducer cells — which mediate T cell pro¬ liferation, lymphokine release and helper cell inter¬ actions for Ig release, and the second class compris- ing T cytotoxic or suppressor cells — which parti¬ cipate in T cell-mediated killing and immune response suppression. In general, these two classes of lymphocytes are distinguished by expression of one of two surface glycoproteins: T4 ( .w. 55,000-62,000 daltons) which is expressed on T helper or inducer cells, probably as a monomeric protein, or T8 (m.w. 32,000 daltons) which is expressed on T cytotoxic or suppressor cells as a dimeric protein. The primary structures of T4 and T8 have been deduced from their respective cDNA sequences [P. J. Maddon et al., "The Isolation and Nucleotide Sequence Of A cDNA Encoding The T Cell Surface Protein T4: A New Member Of The I munoglobulin Gene Family", Cell, 42, pp. 93-104 (1985); D. R. Litt an et al., "The Isolation And Sequence Of The Gene Encoding T8: A Molecule Defining Functional Classes Of T Lympho¬ cytes", Cell, 40, pp. 237-46 (1985)]. Both predicted protein sequences define molecules with domains expected for surface antigens, including transmem- brane and intracytoplasmic domains at the carboxyl end of the protein. In addition, both proteins con¬ tain an amino terminal region which shows striking homology to immunoglobulin and T cell receptor variable regions and which might function during target cell recognition [Maddon et al. , supra] . In im unocompetent individuals, T4 lympho¬ cytes interact with other specialized cell types of the immune system to confer immunity to or defense against infection [E. L. Reinherz and S. F. Schlossman, "The Differentiation Function Of Human T-Cells", Cell, 19, pp. 821-27 (1980)]. More speci¬ fically, T4 lymphocytes stimulate production of growth factors which are critical to a functional immune system. For example, they act to stimulate B cells, the descendants of hemopoietic stem cells, which promote the production of defensive antibodies. They also activate macrophages ("killer cells") to attack infected or otherwise abnormal host cells and they induce monocytes ("scavenger cells") to encompass and destroy invading microbes. It has been found that the primary target of or receptor for certain infective agents is the T4 surface protein. These agents include, for example, viruses and retroviruses. When T4 lympho- cytes are exposed to such agents, they are rendered nonfunctional. As a result, the host's complex immune defense system is destroyed and the host becomes susceptible to a wide range of opportunistic infec¬ tions. Such immunosuppression is seen in patients suffering from acquired immune deficiency syndrome ("AIDS"). AIDS is a disease characterized by severe or, typically, complete immunosuppression and attendant host susceptibility to a wide range of opportunistic infections and malignancies. In some cases, AIDS infection is accompanied by central nervous system disorders. Complete clinical mani¬ festation of AIDS is usually preceded by AIDS related complex ("ARC"), a syndrome accompanied by symptoms such as persistent generalized lymphadeno- pathy, fever and weight loss. The human immunode¬ ficiency virus ("HIV") retrovirus is thought to be the etiological agent responsible for AIDS infection- and its precursor, ARC [M. G. Sarngadharan et al., "Detection, Isolation And Continuous Production Of Cytopathic Retroviruses (HTLV-III) From Patients With AIDS And Pre-AIDS", Science, 224, pp. 497-508 (1984)].* Between 85 and 100% of the AIDS/ARCS popu¬ lation test seropositive for HIV [G. N. Shaw et al., "Molecular Characterization Of Human T-Cell Leukemia (Lymphotropic) Virus Type III In The Acquired Immune Deficiency Syndrome", Science, 226, pp. 1165-70 (1984)]. The number of adults in the United States infected with HIV has been estimated to be between 1 and 2.5 million [D. Barnes, "Strategies For An AIDS Vaccine", Science, 233, pp. 1149-53 (1986); M. Rees, "The Sombre View Of AIDS", Nature, 326, pp. 343-45 (1987)]. These estimates include 64,900 individuals who do not belong to an identified group at risk for AIDS [S. L. Sivak and G.'P. Wormser, "How Common Is HTLV-III Infection In The United States?", New Eng. J. Med. , 313, p. 1352 (1985)]. The apparent annual rate of diagnosis for those infected with HIV virus is between 1 and 2% — a rate which may increase significantly in future years. The genome of retroviruses, such as HIV, contains three regions encoding structural proteins. The gag region encodes the core proteins of the virion. The pol region encodes the virion RNA-depen- dent DNA polymerase (reverse transcriptase) . The * In this application, human immunodeficiency virus ("HIV"), the generic term adopted by the human retrovirus subcommittee of the International Committee On Taxonomy Of Viruses to refer to independent iso- lates from AIDS patients, including human T cell lymphotropic virus type III ("HTLV-III"), lympha- denopathy-associated virus ("LAV"), human immuno¬ deficiency virus type 1 ("HIV-1") and AIDS-associated retrovirus ("ARV") will be used. env region encodes the major glycoprotein found in the membrane envelope of the virus and in the cyto¬ plasmic membrane of infected cells. The capacity of the virus to attach to target cell receptors and to cause fusion of cell membranes are two HIV proper¬ ties controlled by the env gene. These properties are believed to play a fundamental role in the patho- genesis of the virus. HIV env proteins arise from a precursor polypeptide that, in mature form, is cleaved into a large heavily glycosylated exterior membrane protein of about 481 amino acids — gpl20 — and a smaller transmembrane protein of about 345 amino acids which may be glycosylated — gp41 [L. Ratner et al., "Complete Nucleotide Sequence Of The AIDS Virus, HTLV-III", Nature, 313, pp. 277-84 (1985)]. The host range of the HIV virus is asso¬ ciated with cells which bear the surface glycopro¬ tein T4. Such cells include T4 lymphocytes and brain cells [P. J. Maddon et al., "The T4 Gene Encodes The AIDS Virus Receptor And Is Expressed In The Immune System And The Brain", Cell, 47, pp. 333-48 (1986)]. Upon infection of a host by HIV virus, the T4 lymphocytes are rendered non-functional. The progression of AIDS/ARCS syndromes can be correlated with the depletion of T4 lymphocytes, which display the T4 surface glycoprotein. This T cell depletion, with ensuing immunological compromise, may be attri¬ butable to both recurrent cycles of infection and lytic growth from cell-mediated spread of the virus. In addition, clinical observations suggest that the HIV virus is directly responsible for the central nervous system disorders seen in many AIDS patients. The tropism of the HIV virus for T4 cells is believed to be attributed to the role of the T4 cell surface glycoprotein as the membrane-anchored virus receptor. Because T4 behaves as the HIV virus receptor, its extracellular sequence probably plays a direct role in binding HIV. More specifically, it is believed that HIV envelope selectively binds to the T4 epitope(s), using this interaction to initiate entry into the host cell [A. G. Dalgelish et al., "The CD4 (T4) Antigen Is An Essential Component Of The Receptor For The AIDS Retrovirus", Nature, 312, pp. 763-67 (1984); D. Klatzmann et al., "T-Lymphocyte T4 Molecule Behaves As The Receptor For Human Retro- virus LAV", Nature, 312, pp. 767-68 (1984)]. Accord¬ ingly, cellular expression of T4 is believed to be sufficient for HIV binding, with the T4 protein serving as a receptor for the HIV virus. The T4 tropism of the HIV virus has been demonstrated in vitro. When HIV virus isolated from AIDS patients is cultured together with T helper lymphocytes preselected for surface T4, the lympho¬ cytes are efficiently infected, display cytopathic effects, including multinuclear syncytia formation and are killed by lytic growth [D. Klatzmann et al., "Selective Tropism Of Lymphadenopathy Associated Virus (LAV) For Helper-Inducer T Lymphocytes", Science, 225, pp. 59-63 (1984); F. Wong-Staal and R. C. Gallo, "Human T-Lymphotropic Retroviruses", Nature, 317, pp. 395-403 (1985)]. It has been demon¬ strated that a cloned cDNA version of human T4, when expressed on the surface of transfected cells from non-T cell lineages, including murine and fibroblas- toid cells, endows those cells with the ability to bind HIV [P. J. Maddon et al., "The T4 Gene Encodes The AIDS Virus Receptor And Is Expressed In The Immune System And The Brain", Cell, 47, pp. 333-48 (1986)]. During the course of HIV infection, the host mounts both a humoral and a cellular immune response to the virus. These responses include the appearance of antibodies which bind to a number of viral products and which exhibit neutralizing effect or antibody dependent cellular cytotoxic functions [M. Guroff-Robert et al., "HTLV-III-Neutralizing Antibodies In Patients With AIDS And AIDS-Related Complex", Nature, 316, pp. 72-74 (1985); D. D. F. Barin et al., "Virus Envelope Protein Of HTLV-III Represents Major Target Antigen For Antibodies In AIDS Patients", Science, 228, pp. 1094-96 (1985); A. H. Rook et al., "Sera From HTLV-III/LAV Antibody Positive Individuals Mediate Antibody Dependent Cellular Cytotoxicity Against HTLV-III/LAV Infected T Cells", J. Immunol., 138, pp. 1064-68 (1987)]. Epitopes of the HIV envelope have been identified as important determinants in eliciting a neutralizing antibody response. And, determinants in antibody dependent cellular cytotoxicity ("ADCC") activity include HIV env and, possibly, gag epitopes. In the absence to date of effective treat¬ ments for AIDS, many efforts have centered on preven¬ tion of the disease. Such preventative measures include HIV antibody screening for all blood, organ and semen donors and education of AIDS high-risk groups regarding transmission of the disease. Experimental or early-stage clinical treat¬ ment of AIDS and ARCS conditions have included the administration of antiviral drugs, such as HPA-23, phosphonoformate, suramin, ribavirin, azidothymidine ("AZT") and dideoxycytidine, which apparently inter¬ fere with replication of the virus through reverse transcriptase inhibition. Although each of these drugs exhibits activity against HIV in vitro, only AZT has demonstrated potential benefits in clinical trials. AZT administration in effective amounts, however, has been accompanied by undesirable and debilitating side effects, such as bone marrow depression. It is likely, therefore, that hemato- logic toxicity will be a major rate limiting factor in the long term use of AZT. Other proposed methods for treating AIDS have focused on the development of agents having activity against steps in the viral replicative cycle other than reverse transcription. Such methods include the administration of interferons or the application of hybridoma technology. Most of these treatment strategies are expected to require the co-administration of immunomodulators, such as inter- leukin-2. To date, the need exists for he develop¬ ment of effective immunotherapeutic agents and methods for the treatment of AIDS, ARCS, HIV infection and other immunodeficiencies caused by T lymphocyte depletion or abnormalities. DISCLOSURE OF THE INVENTION The present invention solves the problems referred to above by providing, in large amounts, soluble T4 and soluble derivatives thereof that act as receptors for infective agents whose primary target is the T4 surface protein of T4 lymphocytes. Advan¬ tageously, this invention also provides soluble T4 essentially free of other proteins of human origin and in a form that is not contaminated by viruses, such as HIV or hepatitis B virus. As will be appreciated from the disclosure to follow, the DNA sequences and recombinant DNA molecules of this invention are capable of directing, in an appropriate host, the production of soluble T4 or derivatives thereof. The polypeptides of this invention are useful, either as produced in the host or after further derivatization or modification, in a variety of immunotherapeutic compositions and methods for treating immunodeficient patients suffering from diseases caused by infective agents whose primary targets are T4 lymphocytes. According to various embodiments of this invention, such compo- sitions and methods relate to a soluble ' receptor for HIV, soluble T4 proteins and polypeptides and anti¬ bodies thereto. The soluble T4 proteins and polypep¬ tides of this invention include monovalent, as well as polyvalent forms. The compositions and methods of this inven¬ tion, which are based upon soluble T4 proteins, poly¬ peptides or peptides and antibodies thereto, are particularly useful for the prevention, treatment or detection of the HIV-related infections AIDS and ARC. More specifically, the soluble T4-based com¬ positions and methods of this invention employ soluble T4-like polypeptides — polypeptides which advantageously interfere with the T4/HIV interaction by blocking or competitive binding mechanisms which inhibit HIV infection of cells expressing the T4 surface protein. These soluble T4-like polypeptides inhibit adhesion between T4 lymphocytes and infec- . + . . . tive agents which target T4 lymphocytes and inhibit interaction between T4 lymphocytes and antigen pre¬ senting cells and targets of T4 lymphocytes mediated killing. By acting as soluble virus receptors, the compositions of this invention may be used as anti¬ viral therapeutics to inhibit HIV binding to T4 cells and virally induced syncytium formation at the level of receptor binding. This invention accomplishes these goals by providing DNA sequences coding on expression in an appropriate unicellular host for soluble T4 proteins* and soluble derivatives thereof. * As used in this application, "soluble T4 pro¬ tein", "soluble T4" and "soluble T4-like polypeptides" include all proteins, polypeptides and peptides which are natural or recombinant soluble T4 proteins, or soluble derivatives thereof, and which are charac¬ terized by the immunotherapeutic (anti-retroviral) (footnote continued on following page) This invention also provides recombinant DNA molecules containing those DNA sequences and unicellular hosts transformed with them. . Those hosts permit the production of large quantities of the novel soluble T4 proteins, polypeptides, peptides and derivatives of this invention for use in a wide variety of therapeutic, prophylactic and diagnostic compositions and methods. The DNA sequences of this invention are selected from the group consisting of: (a) the DNA inserts of pl99-7, pBG377, pBG380, pBG381, p203-5, pBG391, pBG392, pBG393, pBG394, pBG395, pBG396, pBG397, p211-ll, p214-10 and p215-7; (b) DNA sequences which hybridize to one or more of the foregoing DNA inserts and which code on expression for a soluble T4-like polypeptide; and (c) DNA sequences which code on expression for a soluble T4-like polypeptide coded for on expression by any of the foregoing DNA inserts and sequences. According to an alternate embodiment, this invention also relates to a DNA sequence comprising the DNA insert of pl70-2, said sequence coding on expression for a T4-like polypeptide. And, this invention also relates to recombinant DNA molecules and processes for producing T4 protein using that DNA sequence. (footnote continued from preceding page) or immunogenic activity of soluble T4 protein. They include soluble T4-like compounds from a variety of sources, such as soluble T4 protein derived from natural sources, recombinant soluble T4 protein and synthetic or semi-synthetic soluble T4 protein. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is an autoradiograph depicting the purification of T4 protein from U937 cells by immunoaffinity chromatogr phy. Figure 2 depicts autoradiograph and Western blot data demonstrating that immunoaffinity-purified, solubilized native T4 protein binds to HIV envelope protein. Figure 3 depicts the nucleotide sequence and the derived amino acid sequence of T4 cDNA obtained from PBL clone λ203-4. In this figure, the amino acids are represented by single letter codes as follows: In Figure 3, the T4 protein translation start (AA_ 23 ) is located at the methionine at nucleo- ides 201-203 and the mature N-terminus is located at the lysine (AA 3 ) at nucleotides 276-278. Figure 4 is a schematic outline of the construction of cDNA clones pBG312.T4 (also called P171-1) and pl70-2. Figure 5 is a schematic outline of the construction of plasmid pEClOO. Figure 6 depicts amino acid comparisons at a positions 3, 64 and 231 of various T4 cDNA clones. Figures 7A and 7B depict the protein domain structure of purified,solubilized T4 protein and recombinant soluble T4 mutants. Figures 8A-8D are schematic outlines of constructions of various intermediate plasmids and other plasmids used to express recombinant soluble T4 ("rsT4") of this invention. Figure 9A is a schematic outline of the construction of plasmid pl99-7. Figures 9B and 9C are schematic outlines of the construction of plasmid p203-5. Figure 10 depicts the synthetic oligo¬ nucleotide linkers employed in various constructions according to this invention. Figure 11 depicts the nucleotide sequence of the entire plasmid defined by pl99-7 (P L mutet.rsT4) and its rsT4.2 insert and the amino acid sequence deduced from the rsT4 sequence. This includes the Clal-Clal cassette which defines the Met perfect rsT4.2 coding sequence. Figure 12 depicts a protein blot analysis of an induction of rsT4.2 expression from SG936/pl99-7. Figure 13 is a schematic outline of the construction of plasmid pBG368. Figures 14A-14C are schematic outlines of constructions of various plasmids of this invention. Figure 15 depicts the nucleotide sequence of plasmid pBG391. Figure 16 depicts the nucleotide sequence of plasmid pBG392. In this figure, the T4 protein translation start (AA_ 23 ) is located at the methio- nine at nucleotides 1207-1209 and the mature N-terminus is located at the lysine (AA 3 ) at nucleo¬ tide 1281-84. Figure 17 is a schematic outline of con- structions of various plasmids of this invention. Figure 18 depicts the synthetic oligonucleo¬ tide linkers employed in various constructions according to this invention. Figure 19 depicts the nucleotide sequence of plasmid pBG394. Figure 20 depicts the nucleotide sequence of plasmid pBG396. Figure 21 depicts the nucleotide sequence of plasmid pBG393. Figure 22 depicts the nucleotide sequence of plasmid pBG395. Figure 23 is a Coomassie stained gel of rsT4.2 purified from the conditioned medium of the pBG380 transfected CHO cell line BG380G of plasmid pl96-10. Figure 24 is a schematic outline of the construction of plasmid pl96-10. Figure 25 is a schematic outline of the construction of plasmid pBG394. Figure 26 is a schematic outline of the construction of plasmid p211-ll. Figure 27 is a schematic outline of the construction of plasmid p215-7. Figure 28 is a schematic outline of the construction of plasmid p218-8. Figure 29A is a Coomassie stained gel of rsT4.113.1 purified from the conditioned medium of pBG211-ll transfected E.coli. Figure 29B is an autoradiograph depicting a Western blot analysis of rsT4.113.1 expressed in E.coli. Figure 30, panels (a)-(c) depict the puri¬ fication of rsT4.113.1 from E.coli transformants. Figure 31, panels (a)-(c) depict the refolding of purified rsT4.113.1. Figure 32 is an autoradiograph depicting the immunopreci •pi.tation of 35S-metabolically labelled CHO cell lines producing recombinant soluble T4. Figure 33 depicts an immunoblot analysis of COS 7 cell lines producing recombinant soluble T4. Figure 34 depicts in graphic form the results of a competition assay between rsT4.113.1 and rsT4.3 for binding to 0KT4A or 0KT4. Figures 35-37 depict in graphic form the results of competition assays between rsT4.111 and rsT4.3 for binding to, respectively, 0KT4A, Leu-3A and 0KT4. Figure 38 depicts in graphic form an ELISA assay for rsT4.113.1 from E.coli transformants. Figure 39 depicts in graphic form the results of a p24 radioimmunoassay using recombinant soluble T4 according to this invention. Figures 40 and 41 depict the results of syncytia inhibition assays using recombinant soluble T4 proteins according to this invention. Figure 42 is a schematic outline of the construction of plasmid pBiv.l. Figure 43 depicts the bivalent recombinant soluble T4 protein produced by pBiv.l. DETAILED DESCRIPTION OF THE INVENTION We isolated the DNA sequences of this invention from two libraries: a λgt cDNA library derived the T cell tumor line REX and a λgtlO cDNA library derived from peripheral blood lymphocytes. However, we could also have employed libraries pre¬ pared from other cells that express T4. These include, for example, H9 and U937. We also used a human genomic bank to isolate various fragments of the T4 gene. For screening these libraries, we used a series of chemically synthesized anti-sense oligo¬ nucleotide DNA probes based upon the T4 protein sequence set forth in Maddon et al. (1985), supra. For screening, we hybridized our oligo¬ nucleotide probes to our cDNA libraries utilizing a plaquer hybridization screening assay. We selected clones hybridizing to several of our probes. And, after isolating and subcloning the cDNA inserts of the selected clones into plasmids, we determined their nucleotide sequences and compared the amino acid sequences deduced from those nucleotide sequences to the amino acid sequences referred to in Maddon et al. (1985), supra. As a result of these compari- sons, we determined that all of our selected clones were characterized by cDNA inserts coding for amino acid sequences of human T4. We have depicted in Figure 3 the nucleo¬ tide sequence of full-length T4 cDNA obtained from deposited clone pl70-2 and the amino acid sequence deduced therefrom. That cDNA sequence was subse¬ quently subjected to in vitro site-directed mutagen- esis and restriction fragment substitution so that its cDNA sequence was identical to that of Maddon et al. After modifying our T4 cDNA sequence to be identical to that of Maddon et al. , we truncated samples of it in various positions to remove the coding regions for the transmembrane and intracyto- plasmic domains. The remaining cDNA sequences encoded a soluble T4 which retained the extracellular region believed to be responsible for HIV binding. We then constructed various clones charac¬ terized by such cDNA inserts coding for human soluble T4. Those cDNA sequences may be used in a variety of ways in accordance with this invention. More particularly, those sequences or portions of them, or synthetic or semi-synthetic copies of them, may be used as DNA probes to screen other human or animal cDNA or genomic libraries to select by hybridization other DNA sequences that are related to soluble T4. Typically, conventional hybridization conditions, e.g., about 20° to 27°C below Tm, are employed in such selections. However, less stringent conditions may be necessary when the library is being screened with a probe from a different species than that from which the library is derived, e.g., the screening of a mouse library with a human probe. Such cDNA inserts, portions of them, or synthetic or semi-synthetic copies of them, may also be used as starting materials to prepare various mutations. Such mutations may be either degenerate, i.e., the mutation does not change the amino acid sequence encoded by the mutated codon, or non- degenerate, i.e., the mutation changes the amino acid sequence encoded by the mutated codon. Both types of mutations may be advantageous in producing or using soluble T4's according to this invention. For example, these mutations may permit higher levels of production or easier purification of soluble T4 or higher T4 activity. For all of these reasons, the DNA sequences of this invention are selected from the group con¬ sisting of: (a) the DNA inserts of pl99-7, pBG377, pBG380, pBG381, p203-5, pBG391, pBG392, pBG393, pBG394, pBG395, pBG396, pBG397, p211-ll, p214-10 and p215-7; (b) DNA sequences which hybridize to one or more of the foregoing DNA inserts and which code on expression for a soluble T4-like polypeptide; and (c) DNA sequences which code on expres¬ sion for a soluble T4-like polypeptide coded for on expression by any of the foregoing DNA inserts and sequences. Preferably, the DNA sequences of this invention code for a polypeptide selected from the group consisting of a polypeptide of the formula AA_ 23 -AA 362 of Figure 3, a polypeptide of the formula AA., 362 of Figure 3, a polypeptide of the formula Met-AA 1 _ 3g2 of Figure 3, a polypeptide of the formula AA 1 _ 374 of Figure 3, a polypeptide of the formula Met-AA 1 _ 3 „ 4 of Figure 3, a polypeptide of the formula AA 1 _ 377 of Figure 3, a polypeptide of the formula Met-AA,_ 377 of Figure 3, a polypeptide of the formula AA_ 23 -AA 374 of Figure 3, a polypeptide of the formula AA_ 23 -AA 377 of Figure 3, or portions thereof. DNA sequences according to this invention also preferably code for a polypeptide selected from the group consisting of a polypeptide of the formula AA_ 23 -A 182 of Figure 16, a polypeptide of the formula AA,-AA, a2 of Figure 16, a polypeptide of the formula Met-AA-, 182 of Figure 16, a polypeptide of the formula AA_ 23 -AA 182 of Figure 16, followed by the amino acids asparagine-leucine-glutamine-histidine- serine-leucine, a polypeptide of the formula AA-- A- Q 2 of Figure 16, followed by the amino acids asparagine-leucine-glutamine-histidine-serine-leucine, a polypeptide of the formula Met-AA,_, g2 of Figure 16, followed by the amino acids asparagine-leucine- glutamine-histidine-serine-leucine, a polypeptide of the formula AA_ 23 -AA 113 of Figure 16, a polypeptide of the formula AA 1 -AA 113 of Figure 16, a polypeptide of the formula Met-AA-, , 13 of Figure 16, a polypeptide of the formula AA _ 23 "" AA 111 °^ Fi? 1137 ® 16 ' a polypeptide of the formula AA..-AA.,-., of Figure 16, a polypeptide of the formula Met-AA, ,,, of Figure 16, a polypep- tide of the formula AA_ 23 -AA 131 of Figure 16, a poly- peptide of the formula AA 1 -AA 131 of Figure 16, a polypeptide of the formula Met-AA, , 31 of Figure 16, a polypeptide of the formula ^^- ^ s'^^ l ^ S °^ F ig ure I 6 ' a polypeptide of the formula AA 1 -AA 1 . I - of Figure 16, a polypeptide of the formula Met-AA., 145 of Figure 16, a polypeptide of the formula A_ 23 -AA, 66 of Figure 16, a polypeptide of the formula AA,-AA, , fi of Figure 16, a polypeptide of the formula Met-AA., ,,, of Figure 16, or portions thereof. Additionally, DNA sequences of this inven- tion code for a polypeptide selected from the group consisting of a polypeptide of the formula AA_ 23 ~AA 362 of mature T4 protein, a polypeptide of the formula A ,,,, of mature T4 protein, a polypeptide of the formula Met-AA, 3g2 of mature T4 protein, a polypep¬ tide of the formula A A 1 _ 3 7 4 °f mature T4 protein, a polypeptide of the formula Met-AA, 374 of mature T4 protein, a polypeptide of the formula AA,_ 377 of mature T4 protein, a polypeptide of the formula Met-AA,_ 77 o mature T4 protein, a polypeptide of the formula AA _ 3 -AA 374 of mature T4 protein, a poly¬ peptide of the formula AA_ 23 -AA 377 of mature T4 pro- tein, or portions thereof. DNA sequences according to this invention also code for a polypeptide selected from the group consisting of a polypeptide of the formula AA_ 23 -AA, a2 of mature T4 protein, a polypeptide of the formula AA,-AA, S2 of mature T4 protein, a polypeptide of the " formula Met-AA,_, g2 of mature T4 protein, a polypep¬ tide of the formula AA_ 23 -AA, g2 of mature T4 protein, followed by the amino acids asparagine-leucine- glutamine-histidine-serine-leucine, a polypeptide of the formula AA,-AA, 82 of mature T4 protein, followed by the amino acids asparagine-leucine-glutamine- histidine-serine-leucine, a polypeptide of the formula Met-AA, , 82 of mature T4 protein, followed by the amino acids asparagine-leucine-glutamine- histidine-serine-leucine, a polypeptide of the formula A _ 23 -AA 113 of mature T4 protein, a polypep¬ tide of the formula AA,-AA,, 3 of mature T4 protein, a polypeptide of the formula Met-AA 1 _ 113 of mature T4 protein, a polypeptide of the formula AA_ 23 -AA 11:L of mature T4 protein, a polypeptide of the formula AA,-AA,,, of mature T4 protein, a polypeptide of the formula Met-AA 1 _ 111 of mature T4 protein, a polypep¬ tide of the formula AA_ 23 -A 131 of mature T4 protein, a polypeptide of the formula AA-.-AA-._-. of mature T4 protein, a polypeptide of the formula Met-AA 1 _ 131 of mature T4 protein, a polypeptide of the formula AA_ 23 -AA- 45 of mature T4 protein, a polypeptide of the formula AA 1 -AA 145 of mature T4 protein, a polypep¬ tide of the formula Met-AA- L _ 145 of mature T4 protein, a polypeptide of the formula AA_ 23 -AA,g 6 of mature T4 protein, a polypeptide of the formula AA 1 ~AA- L66 of mature T4 protein, a polypeptide of the formula Met-AA 1 _ 166 of mature T4 protein, or portions thereof. The amino terminal amino acid of mature T4 protein isolated from T cells begins at lysine, the third amino acid of the sequence depicted in Figure 16. Accordingly, soluble T4 proteins also include polypeptides of the formula AA 3 -AA 377 of Figure 16, or portions thereof. Such polypeptides include polypeptides selected from the group consist¬ ing of a polypeptide of the formula AA 3 to AA g62 of Figure 16, a polypeptide of the formula AA 3 to AA 374 of Figure 16, a polypeptide of the formula AA 3 -AA 182 of Figure 16, a polypeptide of the formula AA 3 -AA 113 of Figure 16, a polypeptide of the formula AA 3 ~AA 13 , of Figure 16, a polypeptide of the formula AA 3 -AA, 45 of Figure 16, a polypeptide of the formula AA 3 -AA 166 of Figure 16, and a polypeptide of the formula AA g -AA.,,, of Figure 16. Soluble T4 proteins also include the above-recited polypeptides preceded by an N-terminal methionine group. Soluble T4 protein constructs according to this invention may also be produced by truncating the full length T4 protein sequence at various posi¬ tions to remove the coding regions for the transmem¬ brane and intracytoplasmic domains, while retaining the extracellular region believed to be responsible for HIV binding. More particularly, soluble T4 polypeptides may be produced by conventional tech¬ niques of oligonucleotide directed mutagenesis; restriction digestion, followed by insertion of linkers; or chewing back full length T4 protein with enzymes. Alternatively, soluble T4 polypeptides may be chemically synthesized by conventional peptide synthesis techniques, such as solid phase synthesis [R. B. Merrifield, "Solid Phase Peptide Synthesis. I. The Synthesis Of A Tetrapeptide", J. Am. Chem. Soc, 83, pp. 2149-54 (1963)]. The DNA sequences of this invention code for soluble proteins and derivatives that are believed to bind to Major Histocompatibility Complex antigens and envelope glycoprotein of certain retroviruses, such as HIV. Preferably, they also inhibit syncytium formation, believed to be the mode of intracellular HIV virus spread. And, they may inhibit interaction between T4 lymphocytes and antigen-presenting cells and targets of T4 cell mediated killing. Most preferably, they also inhibit adhesion between T4 lymphocytes and infective agents, such as the HIV virus, whose primary targets are T4 lymphocytes. The DNA sequences of this invention are also useful for producing soluble T4 or its deriva¬ tives coded for on expression by them in unicellular hosts transformed with those DNA sequences. As well known in the art, for expression of the DNA sequences of this invention, the DNA sequence should be opera- tively linked to an expression control sequence in an appropriate expression vector and employed in that expression vector to transform an appropriate unicellular host. Such operative linking of a DNA sequence of this invention to an expression control sequence, of course, includes the provision of a translation start signal in the correct reading frame upstream of the DNA sequence. If the particular DNA sequence of this invention being expressed does not begin with a methionine, the start signal will result in an additional amino acid — methionine — being located at the N-terminus of the product. While such methionyl-containing product may be employed directly in the compositions and methods of this invention, it is usually more desirable to remove the methionine before use. Methods are available in the art to remove such N-terminal methionines from polypeptides expressed with them. For example, certain hosts and fermentation conditions permit removal of substantially all of the N-terminal methionine in vivo. Other hosts require in vitro removal of the N-terminal methionine. However, such in vivo and in vitro methods are well known in the art. A wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences, such as various known derivatives of SV40 and known bacterial plasmids, e.g., plasmids from E.coli including col El, pCRl, pBR322, pMB9 and their derivatives, wider host range plasmids, e.g., RP4, phage DNAs, e.g., the numerous derivatives of phage λ, e.g., NM989, and other DNA phages, e.g., M13 and filamenteous single stranded DNA phages, yeast plas- mids, such as the 2μ plasmid or derivatives thereof, and vectors derived from combinations of plasmids and phage DNAs, such as plasmids which have been modified to employ phage DNA or other expression control sequences. For animal cell expression, we prefer to use plasmid pBG368, a derivative of pBG312 [R. Cate et al., "Isolation Of The Bovine And Human Genes For Mullerian Inhibiting Substance And Expression Of The Human Gene In Animal Cells", Cell, 45, pp. 685-98 (1986)] which contains the major late promoter of adenovirus 2. In addition, any of a wide variety of expression control sequences — sequences that con- trol the expression of a DNA sequence when opera¬ tively linked to it — may be used in these vectors to express the DNA sequence of this invention. Such useful expression control sequences, include, for example, the early and late promoters of SV40 or the adenovirus, the lac system, the trp system, the TAG or TRC system, the major operator and promoter regions of phage λ, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, e.g., Pho5, the promoters of the yeast α-mating factors, the polyhedron promoter of the baculovirus system and other sequences known to control the expression of genes of prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. For animal cell expression, we prefer to use an expression control sequence derived from the major late promoter of adenovirus 2. A wide variety of unicellular host cells are also useful in expressing the DNA sequences of this invention. These hosts may include well known eukaryotic and prokaryotic hosts, such as strains of E.coli, Pseudomonas, Bacillus, Streptomyces, fungi, such as yeasts, and animal cells, such as CHO and mouse celis, African green monkey cells, such as COS 1, COS 7, BSC 1, BSC 40, and BMT 10, insect cells, and human cells and plant cells in tissue culture. For animal cell expression, we prefer CHO cells and COS 7 cells. It should of course be understood that not all vectors and expression control sequences will function equally well to express the DNA sequences of this invention. Neither will all hosts function equally well with the same expression system. Ξow- ever, one of skill in the art may make a selection among these vectors, expression control sequences, and hosts without undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must replicate in it. The vector's copy number, the ability to control that copy number, and the expression of any other proteins encoded by the " vector, such as antibiotic markers, should also be considered. In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the system, its controllability, and its compatibility with the particular DNA sequence of this invention, particularly as regards potential secondary struc¬ tures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the product coded for on expression by the DNA sequences of this invention to them, their secretion characteristics, their ability to fold proteins correctly, their fermentation re- quirements, and the ease of purification of the products coded on expression by the DNA sequences of this invention. Within these parameters, one of skill in the art may select various vector/expression control system/host combinations that will express the DNA sequences of this invention on fermentation or in large scale animal culture, e.g., CHO cells or COS 7 cells. The polypeptides produced on expression of the DNA sequences of this invention may be isolated from the fermentation or animal cell cultures and purified using any of a variety of conventional methods. One of skill in the art may select the most appropriate isolation and purification tech¬ niques without departing from the scope of this invention. The polypeptides produced on expression of the DNA sequences of this invention are essentially free of other proteins of human origin. Thus, they are different than T4 protein purified from human lymphocytes. The polypeptides of this invention are useful in immunotherapeutic compositions and methods. For example, the polypeptides of this invention are active in inhibiting infection by agents whose primary targets are T4 lymphocytes by interfering with their interaction with those target lymphocytes. More preferably, the polypeptides of this invention may be employed to saturate the T4 receptor sites of T4- targeted infective agents. Thus, they exert anti¬ viral activity by competitive binding with cell surface T4 receptor sites. This effect is plainly of great utility in diseases, such as AIDS, ARC and HIV infection. Accordingly, the polypeptides and methods of this invention may be used to treat humans having AIDS, ARC, HIV infection or antibodies to HIV. In addition, these polypeptides and methods may be used for treating AIDS-like diseases caused by retroviruses, such as simian immunodeficiency viruses, in mammals, including humans. According to one embodiment of this inven¬ tion, antibodies to soluble T4 proteins and polypep- tides may be used in the treatment, prevention, or diagnosis of AIDS, ARC and HIV infection. The polypeptides of this invention may also be used in combination with other therapeutics used in the treatment of AIDS, ARC and HIV infection. For example, soluble T4 polypeptides may be used in combination with anti-retroviral agents that block reverse transcriptase, such as AZT, ΞPA-23, phos¬ phonoformate, suramin, ribavirin and dideoxyciti- dine. Additionally, these polypeptides may be used with anti-viral agents such as interferons, includ¬ ing alpha interferon, beta interferon and gamma interferon, or glucosidase inhibitors, such as castanospermine. Such combination therapies advan¬ tageously utilize lower dosages of those agents, thus avoiding possible toxicity. And, the polypeptides of this invention may be used in plasmapheresis techniques or in blood bags for selective removal of viral contaminants from blood. According to this embodiment of the invention, soluble T4 polypeptides may be coupled to a solid support, comprising, for example, plastic or glass beads, or a filter, which is incorporated into a plasmapheresis unit. Additionally, the compositions of this invention may be employed as im unosuppressants use¬ ful in preventing or treating graft-vs-host disease, autoimmune diseases and allograft rejection. The compositions of this invention typi¬ cally comprise an immunotherapeutic effective amount of a polypeptide of this invention and a pharmaceu¬ tically acceptable carrier. Therapeutic methods of this invention comprise the step of treating patients in a pharmaceutically acceptable manner with those compositions. The compositions of this invention for use in these therapies may be in a variety of forms. These include, for example, solid, semi-solid and liquid dosage forms, such as tablets, pills, powders, liquid solutions or suspensions, liposomes, supposi¬ tories, injectable and infusable solutions. The preferred form depends on the intended mode of admin- istration and therapeutic application. The composi¬ tions also preferably include conventional pharma¬ ceutically acceptable carriers and adjuvants which are known to those of skill in the art. Generally, the pharmaceutical compositions of the present invention may be formulated and admin¬ istered using methods and compositions similar to those used for other pharmaceutically important poly- peptides (e.g., alpha-interferon). Thus, the poly¬ peptides may be stored in lyophilized form, reconsti¬ tuted with sterile water just prior to administration, and administered by the usual routes of administration such as parenteral, subcutaneous, intravenous, intra¬ muscular or intralesional routes. An effective dosage may be in the range of from 0.5 to 5.0 mg/kg body weight/day, it being recognized that lower and higher doses may also be useful. This invention also relates to soluble receptors and their use in diagnosing or treating viral agents which target or bind to those receptors. Such soluble receptors may be used as decoys to absorb viral agents and to halt the spread of viral infection. Alternatively, virus-killing agents may be attached to the soluble protein receptors, providing a direct mode of delivery of those agents to the virus. More particularly, the polypeptides of this invention are useful in diagnostic compositions and methods to detect or monitor the course of HIV infection. Advantageously, these polypeptides are useful in diagnosing variants of the HIV virus, regardless of origin of the infecting HIV agent. For example, soluble T4 proteins and poly¬ peptides according to this invention, which have a high affinity for HIV, may be advantageously used to increase the sensitivity of HIV assay systems now based upon monoclonal or polyclonal antibodies. More specifically, soluble T4 proteins and polypep¬ tides may be used to pretreat test plasma to concen¬ trate any HIV present, even in small amounts, so that it is more easily recognized by the antibody. And soluble T4 proteins and polypeptides may be used to purify the HIV envelope protein gpl20. Alternatively, the soluble T4 proteins and polypeptides of this invention may be used to replace anti-HIV antibodies now used in various assays. These soluble T4 proteins and polypeptides are be preferable to anti-HIV antibodies for two reasons. First, soluble T4, exhibits an affinity for HIV of approximately 10 -9, a level which exceeds the 10-7 to 10 —8 values of anti-HIV antibodies. And, while anti-HIV antibodies are more likely to be specific for different HIV isolates, strain variations would not affect a soluble T4 protein-based assay, since all HIV isolates must be capable of interacting with the T4 receptor as a prerequisite to infectivity. For example, a soluble T4 protein or poly¬ peptide may be linked to an indicator, such as an enzyme, and used in an ELISA assay. Here, soluble T4 advantageously acts as a measure of both HIV in a test sample and any free HIV envelope gpl20 protein. And, polyvalent forms of soluble T4 proteins or polypeptides may be produced, for example, by chemical coupling or genetic fusion techniques, thus increasing even further the avidity of soluble T4 for HIV. In order that this invention may be better understood, the following examples are set forth. These examples are for purposes of illustration only, and are not to be construed as limiting the scope of the invention in any manner. EXAMPLES Purification Of Native Solubilized T4 We purified native T4 from the T4 -promono- cytic cell line U937 derived from a histocytic lymphoma to approximately 50% purity usir.g immuno¬ affinity chromatography as follows. We grew U937 cells [a gift from Dr. Scott Hammer, New England Deaconess Hospital] to IO 6 cells/ml in RPMI 1640, 10% FCS, harvested and washed them in IX PBS. We then lysed the cell pellet in 20 mM Tris-HCl (pH 7.7), 0.5% NP-40 (a non-ionic detergent), 0.2% NaDOC, 0.2 mM EGTA, 0.2 mM PMSF and 7 5 μg/ml BPTI at 4 x 10 cells/ml. Because this purification was carried out in the presence of a non-ionic detergent, T4, which is normally membrane- bound via its hydrophobic transmembrane domain, was isolated as a soltibilized protein. We spun the lysate in a GS 3 rotor for 10 min at 10,000 rpm and stored the supernatant at -70°C. Subsequently, we preabsorbed the clarified cell extract with mouse IgG-Sepharose, followed by protein A Sepharose and then passed the flowthrough through an immunoaffinity column comprising immobil¬ ized 19Thy anti-T4 monoclonal antibody on Affigel-10 [a gift from Dr. Ellis Reinherz, Dana Farber Cancer Institute, Boston, Massachusetts]. We washed the column extensively and eluted the bound material with 50 mM glycine-HCl (pH 2.5), 0.15 M NaCl, 0.5% NP-40, 5 μg/ml BPTI and 0.2 mM EGTA. We then separated 10 μl aliquots of each elution fraction on a 10% SDS-PAGE under reducing conditions, with the bands being visualized by silver staining. As shown in Figure 1, a major silver- stained band of 55 Kd was visible. We then carried out two assays on the 55 Kd protein and sequenced the amino terminus of the protein to confirm its identity as native solubilized T4. Sequencing Of Native Solubilized T4 We determined the N-terminal amino acid sequence of our solubilized native T4 which we isolated from a detergent extract of U937 cells by immunoaffinity chromatography as described above. Techniques for determining the amino acid sequences of various proteins and peptides derived from them are well known in the art. We chose auto¬ mated Edman degradation to determine the amino terminus of our solubilized native T4. More speci¬ fically, we gel purified and electroeluted approxi¬ mately 5 μg of the solubilized native T4 and then subjected it to automated Edman degradation using a gas phase sequencer (Applied Biosystems 47OA) . We then identified the PTH-amino acids produced at each cycle of the Edman chemistry by high pressure liquid chromatography, on-line with the sequencer, in a PTH-amino acid analyzer (Applied Biosystems 120A). Direct analysis of the protein provided amino terminal sequence information which, when compared to the amino acid sequence deduced from the cDNA sequence of human T4 [Maddon et al. (1985), supra], identified the purified protein as human T4. Radioimmunoassay Of Native Solubilized T4 To determine that our purification process enriched for T4, we assayed fractions from the immunoaffinity elution step in a T4-specific sandwich radioimmunoassay, based upon the ELISA assay of P. E. Rao et al., in Cellular Immunology, 80, pp. 310-19 (1983). We coated each well of a Removawell strip (Dynatech Labs, Alexandria, Virginia) with 50 μl of 10 μl/ml 0KT4 antibody (ATCC #CRL 8002) or MOPC195 (a background binding control) in 0.05 M sodium bicarbonate buffer (pH 9.4) at 4°C overnight. We washed the wells and then filled them with 1% FCS in PBS to saturate the protein binding capacity of the plastic. After removing the 1% FCS solution, we added test samples, in 50 μl aliquots, to the wells. We then incubated the samples for 4 hours at room temperature. Subsequently, we removed the samples and washed the wells four times with 0.05% Tween-20 m PBS. We then added 125I-labelled 19Thy antibody (50,000-100,000 cp per well) and incubated the wells at 4°C overnight. We then washed the wells four times and separated each well for bound 125I detection in a Beckman gamma detector. As shown in Figure 1, in which values were plotted following subtraction for background, the peak fraction of solubilized native T4 protein detected by radioimmunoassay coincided with elution of the 55 Kd protein seen by silver staining. Western Blot Assay For T4 Although many antibodies have been developed for detecting T4 antigen, none are useful for protein blot analysis (Dr. Ellis Reinherz, personal communi¬ cation). In order to develop antibodies useful for Western blot detection of soluble T4 to follow the purification of T4 and recombinant soluble T4, we raised polyclonal, hyperimmune anti-T4 antisera in rabbits against three synthetic T4 oligopeptides. These oligopeptides are represented in Figure 3 as follows: Oligopeptide Amino Acid Coordinates JB-1 44-63 JB-2 133-156 JB-3 325-343 We had previously synthesized these peptides using conventional phosphoamide DNA synthesis techniques. See, e.g., Tetrahedron Letters, 22, pp. 1859-62 (1981). We synthesized the peptides on an Applied Biosystems 380A DNA Synthesizer and purified them by gel electrophoresis. (i) Coupling Of T4 Peptides To BTG We coupled each of these peptides to the carrier protein bovine thyrogobulin ("BTG") [Sigma, St. Louis, Missouri] according to a modification of procedures set forth in J. Rothbard et al., J. Exp. Med., 160, pp. 208-21 (1984) and R. C. Kennedy et al., "Antiserum To A Synthetic Peptide Recognizes The HTLV-III Envelope Glycoprotein", Science, 231, pp. 1556-59 (1986). More specifically, we mixed 10 mg of BTG diluted in 1 ml of PBS with 1.3 mg of m-maleimido- benzoyl-N-hydroxysuccinimide ester ("MBS") in 0.5 ml of dimethylformamide ("DMF"). We mixed the reaction mixture well and reacted it for about 1 hour at 25°C. Subsequently, we loaded the mixture onto a Sephadex G25 gel filtration column (Pharmacia, Sweden) which had been pre-equilibrated with 0.1 M PBS (pH 6.0). We then collected a total of thirty 2 ml aliquot elution fractions and read the absorbance of each fraction at 280 nm We then pooled the three peak fractions (15, 16 and 17) to create the activated carrier. We dissolved 10 mg of NaBH 4 in 2.5 ml of 0.1 M sodium borate solution to produce a sodium borohydride solution. Subsequently, we diluted approximately 8 mg of each of synthetic T4 peptides JB-1, JB-2 and JB-3 with 1 ml of 0.1 M borate buffer and then mixed each solution with 200 μl of the sodium borohydride solution, incubating the mixture on ice for 5 minutes. We then warmed each peptide solution to 25°C, brought each solution to pH 1.0 with 1 N HCl (during which frothing occurred) and then brought each solution to pH 7.0 with 1 N NaOH (after the frothing had stopped) . We then coupled each peptide to BTG by adding 1.2 ml of the peptide solution to 6 ml of the activated carrier solution. We allowed the coupling reaction to proceed overnight by incubating the reac¬ tion mixture at room temperature. (ii) Inoculation Of Test Animals We dissolved each of the BTG-coupled pep- tides prepared above in sterile Freund's complete adjuvant, to a final concentration of 1 μg/ml coupled peptide in PBS. Subsequently, we inoculated each of three rabbits (New Zealand white) by intramuscular injection of 500 μg of one of the coupled peptides into each rabbit. We inoculated a fourth rabbit (New Zealand white) in the same manner with a mixture of the three coupled peptides. All rabbits were prebled prior to boosting to establish an average baseline for each response to be measured. The rabbits were boosted at 6 weeks with 500 μg coupled peptide in incomplete Freund's adjuvant. Serum was collected from each rabbit monthly for 4 months after immunization. The serum was then assayed for antipeptide titer. (iii) ELISA With Antipeptide Sera Against Peptide Coated Plates In this assay, we determined that antiserum raised in an animal by each of peptides JB-1, JB-2 and JB-3 binds to that peptide. Accordingly, those peptides are immunogenic and elicit a response in test animals. To carry out the assay, we coated Immulon-2 (Dynatech Labs, Alexandria, Virginia) microtiter plates with 50 μl per well of 50 μg/ml -uncoupled peptide in PBS and incubated the plates overnight at 4°C. Plates coated with peptide 46R*, which served as controls, were treated identically. We then washed the plates 4 times with PBS-Tween (0.5%) and 4 times with water. The plates were blotted dry by gentle tapping over paper towels. After blotting the plates, * Peptide 46 corresponds to amino acids ("AA") 728-751 of the env gene of the HIV genome. The amino acid numbering corresponds to that set forth for the env gene in L. Ratner et al., "Complete Nucleotide Sequence Of The AIDS Virus, HTLV-III", Nature, 313, pp. 277-84 (1985). Peptide 46 has the sequence: LPIPRGPDRPEGIEEEGGERDRDR. we added 200 μl of a 5% FCS/PBS solution to each well and incubated the plates for 1 hour at room temperature. We then assayed serum samples from the rabbits on the pre-coated plates prepared as described above. We assayed the antibody response to the immunogen peptide at an initial dilution of 1:100, followed by serial 10-fold dilutions in 5% FCS/PBS. After a 2 hour incubation period at room temperature, we washed the plates and blotted them dry as described above. We then added 50 μl of a 1:1500 dilution of horseradish peroxidase ("HRP")- conjugated goat anti-rabbit-IgG [Cooper Biomedical, Malvern, Pennsylvania] in 5% FCS/PBS to each well and incubated the plates at room temperature for 1 hour. We washed the plates with PBS-Tween 0.5%. We then added 50 μl of 0.42 mM TMB. We stopped the enzyme reactions with 50 μl of 2 M H 2 S0 4 - We then analyzed the plates spectrophotometrically at 450 nm using a microtiter " plate reader [Dynatech Labs, Alexandria, Virginia] . We observed that antiserum against each of peptides JB-1, JB-2 and JB-3 binds to the. corre¬ sponding peptide. We also observed that antiserum against a mixture of peptides JB-1, JB-2 and JB-3 binds to peptides JB-1 and JB-3 under the conditions set forth above. The- titers of each of the four antisera tested against the peptides in the solid- phase ELISA are shown below, where "ND" represents values not determined: Approximate Titer Against: Ig fractions from two of the three anti¬ peptide sera raised against individual peptides, anti-JB-1 and anti-JB-2, recognized the 55 Kd T4 antigen band of native solubilized T4 in a Western blot analysis of protein eluted from the 19Thy (anti-T4) monoclonal antibody affinity column described above. As in the case of the radioimmuno¬ assay of native solubilized T4, the detection of the 55 Kd protein coincides with its apparent elution from the affinity column. This provides further evidence that our T4 purification procedure enriched for solubilized T4. Thus, these polyclonal sera are useful in the detection of nanogram quantities of T4 (both native and recombinant forms) by Western analysis. Binding of Cell-Free T4 To HIV Envelope We then tested our purified solubilized native T4 isolated from U937 cells for its ability to bind to the HIV envelope protein gpl60/gpl20. To carry out this direct binding assay, we incubated 35 S-labelled gpl60/gpl20 detergent cell extract derived from a recombinant cell line 7d2 (a gift from Drs. Mark Kowalski and William Haseltine, Dana- Farber Cancer Institute) with samples of solubilized native T4, each of which had been preincubated with one type of monoclonal antibody. More specifically, we mixed 5 μl of solu¬ bilized T4 in a microfuge tube with 5 μg (about 3 μl) of 0KT4 (ATCC #CRL 8002), a monoclonal antibody recognizing an epitope on T4 which does not interfere with HIV binding [J. A. Hoxie et al., J. Immunol., 136, pp. 361-63 (1986)] or with 5 μg of 0KT4A (Ortho Diagnostics #7142), a monoclonal antibody that inter¬ feres with HIV binding to T4 positive cells [J. Steven McDougal et al., J. Immunol., 137, pp. 2937-2944 (1986)]. Alternatively, we mixed 50 μl of solubilized T4 with 5 μg of αHTLV III gpl20 (Dupont #NEN-9284). We then incubated the mixtures on ice for 1 hour. Subsequently, we added 150 μl of 35S- labelled gpl60/gpl20 cell extract or 35S-labelled control cell extract (precleared with protein-A Sepharose) to the preincubated solubilized T4/mono- clonal antibody mixtures and rocked the tubes over¬ night at 4°C. We then precipitated the T4/gpl60/gpl20 immune complexes by adding 30 μl of protein-A Sepharose to each tube and rocking for 2 hours at 4°C to allow the protein-A Sepharose to bind to the antibody complexes. Subsequently, we spun down the beads in an Eppendorf microfuge and after extensive washings, we eluted with 40 μl SDS sample buffer at 65°C for 10 minutes. We then loaded 20 μl of the eluted material on a 7.5% SDS-PAGE gel which was run under reducing conditions. Figure 2 depicts autoradiograph and Western blot results of the T4/gpl60/gpl20 coim unoprecipita- tions. In Figure 2, lanes 1-5 were autoradiographed after treatment with 40% sodium salicylate and lanes 6-7 were developed on a Western blot with rabbit antisera JB-2. As shown in Figure 2, gpl60/gpl20 protein was coimmunoprecipitated in the presence of T4 with 0KT4 (lane 5) but not in the presence of T4 with 0KT4A (lane 4). Lane 3 shows the positive control for gpl60/gpl20 using αHTLV III gpl20 monoclonal antibody. Neither negative control with 35S-labelled control extract (lane 1) or protein-A Sepharose alone (lane 2) showed bands migrating in the position of gpl60/gpl20. Based upon the bands that developed on the Western blot, the amount of T4 precipitated with either 0KT4 (lane 6) or 0KT4A (lane 7) appeared to be similar. This demonstrates that purified, solubilized native T4, which is naturally membrane bound, can still interact with the HIV glycoprotein in solution. Accordingly, we believe that cell free soluble T4 is useful in preventing the binding interaction between HIV and the T4 receptor of 14 lymphocytes. By com- peting with cell surface T4 for binding to the HIV envelope protein gpl20, soluble T4 is useful in block¬ ing HIV infection. Synthesis Of Oligonucleotide DNA Probes The nucleotide sequence and a deduced amino acid sequence for a cDNA that purportedly encodes the entire human T4 protein have been reported [Maddon et al. , (1985), supra]. The deduced primary structure of the T4 protein reveals that it can be divided into domains as demonstrated below: Amino Acid Structure/Proposed Location Coordinates Hydrophobic/Secretory Signal -23 to -1 Homology to V-Regions/ Extracellular +1 to +94 Homology to J-Regions/ Extracellular +95 to +109 Glycosylated Region/ Extracellular +110 to +374 Hydrophobic/Transmembrane Sequence +375 to +395 Very Hydrophilic/ Intracytoplasmic +396 to +435 Based on the sequence for the above-listed domains, we chemically synthesized antisense oligonucleotide DNA probes using conventional phos- phoamide DNA synthesis techniques. See, e.g., Tetrahedron Letters, 22, pp. 1859-62 (1981). We synthesized the probes on an Applied Biosystems 380A DNA synthesizer and purified them by gel electro- phoresis. Furthermore, we synthesized the probes such that they were complementary to the DNA sequences which code for the amino acid sequence, i.e., the probes were antisense, to enable them to recognize and hybridize to the corresponding sequences in DNA, as well as in mRNA. The nucleotide sequences of the eleven selected regions of the T4 protein [corresponding to the nucleotide numbering set forth in Maddon et al. , (1985), supra] were the following: Before using our DNA probes for screening, we 5' end-labelled each of the single-stranded DNA probes with 32P usi.ng [γ-32P]-ATP and T4 polynucleo- tide kinase, substantially as described by A. M. Maxam and W. Gilbert, "A New Method For Sequencing DNA", Proc. Natl. Acad. Sci. USA, 74, pp. 560-64 (1977). Construction of λgtlO Peripheral Blood Lymphocytes cDNA Library To prepare our Peripheral Blood Lymphocytes (PBL) cDNA library, we processed PBL, from a single leukophoresis donor, through one round of absorption to remove monocytes. We then stimulated the non- adherent cells with IFN-γ 1000 U/ml and 10 μg/ml PHA for 24 hours. We isolated RNA from these cells using phenol extraction [Maniatis et al., Molecular Cloning, p. 187 (Cold Spring Harbor Laboratory) (1982)] and , prepared poly A mRNA by one round of oligo dT cellu¬ lose chromatography. We ethanol precipitated the RNA, dried it in a speed vac and resuspended the RNA in 10 μl H 2 0 (0.5 μg/μl). We treated the RNA for 10 min at room temperature in CH 3 HgOH (5 mM final con¬ centration) and β-mercaptoethanol (0,26 M). We then added the methyl mercury treated RNA to 0.1 M Tris-HCl (pH 8.3) at 43°C, 0.01 M Mg, 0.01 M DTT, 2 mM Vanadyl complex, 5 μg oligo 20 ιτ - w - KC1, 1 π»M dCTP, dGTP, dTTP, 0.5 mM d 2 μCi[α- 32 P]dATP and 30 U 1.5 μl AMV reverse transcriptase (Seikagaku America) in a total volume of 50 μl. We incubated the mixture for 3 minutes at room temperature and then for 3 hours at 44°C, after which time we stopped the reaction by the addition of 2.5 μl of 0.5 M EDTA. We extracted the reaction mixture with an equal volume of phenol:chloroform (1:1) and precipi¬ tated the aqueous layer two times with 0.2 volume of 10 M NH-AC and 2.5 volumes EtOH and dried it under vacuum. The yield of cDNA was 1.5 μg. We synthesized the second strand according to the methods of Okayama and Berg [Mol. Cell. Biol., 2, p. 161 (1982)] and Gubler and Hoffman [Gene, 25, pp. 263-69 (1983)], except that we used the DNA poly- merase I large fragment in the synthesis. We blunt ended the double-stranded cDNA by resuspending the DNA in 80 μl TA buffer (0.033 M Tris Acetate (pH 7.8); 0.066 M KAcetate; 0.01 M MgAcetate; O.OOIM DTT; 50 μg/ml BSA), 5 μg RNase A, 4 units RNase H, 50 μM β NAD , 8 units E.coli ligase, 0.3125 mM dATP, dCTP, dGTP, and dTTP, 12 units T. polymerase and incubated the reaction mixture for 90 min at 37°C, added 1/20 volume of 0.5M EDTA, and extracted with phenol:chloroform. We chromatographed the aqueous layer on a G150 Sephadex column in 0.01M Tris-HCl (pH 7.5), 0.1 M NaCl, 0.001 M EDTA and collected the lead peak containing the double-stranded cDNA and ethanol precipitated it. Yield: 0.605 μg cDNA. We ligated the double-stranded cDNA to linker 35/36: 5'AATTCGAGCTCGAGCGCGGCCGC3' 3• GCTCGAGCTCGCGCCGGCG5' using standard procedures. We then size selected the cDNA for 800 bp and longer fragments on a S500 Sephacryl column, and ligated it to EcoRI-digested bacteriophage lambda vector gtlO (a gift of Dr. Ellis Reinherz). We packaged aliquots of the ligation reaction in Gigapak (Strategene) according to the manufacturer's protocol. We used the packaged phage to infect E.coli BNN102 cells and plated the cells for amplification. - The resulting library con- tained 1.125 x 10 independent recombinants. We also screened a PBL cDNA library in the bacteriophage lambda vector gtlO (a gift of Dr. Ellis Reinherz), which was synthesized from mRNA from a + T4 tumor cell line named REX, which expresses T4 protein at high levels [O. Acuto et al., "The Human T Cell Receptor: Appearance In Ontogeny And Biochemical Relationship Of Lambda and Beta Subunits on IL-2 Dependent Clones And T Cell Tumors", Cell, 34, pp. 717-26 (1983)]. Screening Of The Libraries We then used three of our 32P-labelled synthetic oligonucleotide antisense probes, probes 3, 6 and 9, to screen in parallel our two λgtlO cDNA libraries using the plaque hybridization screening technique described in R. Cate et al., "Isolation Of The Bovine And Human Genes For Mullerian Inhibiting Substance And Expression Of The Human Gene In Animal Cells", Cell, 45, pp. 685-98 (1986), with minor modi ications. We modified the Cate et al. proce- dure by hybridizing without tetramethyl ammonium chloride to accommodate our use of unique probes, rather than mixtures, to probe the plaque filters. We used the three probes, which had been previously 5' end-labelled with [γ- 32P]-ATP according to the method of A. Maxam and W. Gilbert, Meth. Enzymol., 68, pp. 499-80 (1979) to screen in parallel the PBL cDNA library and the REX cDNA library dis¬ cussed above. From our screening of the PBL library, we isolated a nearly full length soluble T4 cDNA clone — λ203-4 (or λgtl0.PBL.T4) — containing a 3.064 kb insert which could be cleaved from the λgtlO vector with EcoRI. From our screening of the REX cell library, we isolated an incomplete T4 cDNA clone containing a 1,200 bp cDNA insert. We then further characterized the DNA from these clones by DNA sequencing analysis. We also screened a bacteriophage lambda human genomic library, constructed in the vector EMBL3 by Dr. Mark Pasek (Biogen Inc., Cambridge, Massachusetts) [N. Murray in Lambda 2, eds. R. Hendrix, J. Roberts, F. Stahl, R. Weisberg, pp. 3935-422 (1983)] The library contains DNA fragments, created by partial restriction of chromosomal DNA from the human lympho- blastid cell line GM1416,48, XXXX (Human Genetic Mutant Cell Repository, Camden, New Jersey) with Sau3a, ligated onto EMBL3 arms which had been sub¬ jected to cleavage with BamHI according to the pro¬ cedures outlined in Maniatis et al. , (1982), supra. Plating of the phage library, lysis, and transfer of the phage DNA onto nitrocellulose were performed as described by W. D. Benton and R. W. David, "Screening of Lambda gt Recombinant Clones By Hybridization To Single Plaques In Situ", Science, 196, p. 180 (1977) and Maniatis et al. (1982). Hybridization conditions were those described by Cate et al. (1986), supra, except that tetramethylammonium chloride (TMAC1) was omitted from the washing buffer. Approximately 2 million plaques were screened in parallel hybridizations with probe 1 and probe 3 discussed above. One phage, called CM47, which hybridized with probe 3 in the primary screenings, was subjected to DNA sequence analysis to determine the existence and position of an intron between the coding sequences for the predicted extra¬ cellular and transmembrane domains. No phage clones containing T4 sequences were found screening with probe 1, probably because it includes a sequence interrupted by an intron [D. R. Littman and S. N. Gettner, Nature, 325, pp. 453-55 (1987); and our observations] . Partial sequence analysis of CM47 shows that an intron interrupts the sequence corresponding to the codon for valine (amino acid 363) of the deduced primary sequence for T4 (Figure 3 — in which introns are indicated by a solid line). This intron defines a potential site for introducing a stop codon in order to express a soluble form of T4. Another intron found within the coding sequence for T4 inter¬ rupts the codon for arginine (amino acid 295) and a third intron in CM47 is found between the codons for arginine (amino acid 402) and arginine (amino acid 403) (Figure 3). Sequencing Of cDNA Clones We then subcloned EcoRI digested DNA from clone λ203-4 into animal expression vector pBG312 [R. Cate et al. , supra] to facilitate sequence analysis. More specifically, as depicted in Figure 4, we then digested λgtlO.PBL.T4 with EcoRI to excise the 3.064 kbp EcoRI-EcoRI fragment containing the full length T4 cDNA. This cDNA sequence, including the entire coding region for soluble T4 and for full length T4 was deposited in pl70-2. We used T4 ligase to ligate the fragment into animal expression vector pBG312 [supra] which had been previously cut with EcoRI, to form pBG312.T4 and pl70-2 (Figure 4). We then determined the nucleotide sequence of the EcoRI fragment of pBG312.T4 using Maxam Gilbert technology [A. M. Maxam and W. Gilbert, "A New Method For Sequencing DNA", Proc. Natl. Acad. Sci. USA, 74, pp. 560-64 (1977)] (see Figure 3, which depicts the PBL cDNA sequence in comparison to that reported by Maddon et al. , (1985), supra). This analysis showed that the 3.064 kbp PBL full length complementary DNA copy of T4 cDNA contained the coding sequence for T4, approximately 200 bp of 5' noncoding sequence and approximately 1500 bp of 3' noncoding sequence. We then cut pBG312.T4 with PstI and removed the resulting 3' protruding ends with Klenow and isolated an approximately 2.5 kbp fragment. We then inserted the fragment into the polylinker of pBG312 (which had been previously restricted at the Smal site) to form plasmid pl70-2, which contains the full length PBL T4 cDNA sequence (see Figure 3). As depicted in Figure 3, the PBL T4 cDNA contains a nucleotide sequence almost identical to the approximately 1,700 bp sequence reported by Maddon et al. , (1985), supra. The PBL T4 cDNA, how¬ ever, contains three nucleotide substitutions that, in the translation product of this cDNA, would pro¬ duce a protein containing three amino acid substi¬ tutions compared to the sequence reported by Maddon et al. As shown in Figure 3, these differences are at amino acid position 3, where the asparagine of Maddon et al. is replaced with lysine; position 64, where the tryptophan of Maddon et al. is replaced with arginine and at position 231, where the phenyl- alanine of Maddon et al. is replaced with serine. The asparagine reported at position 3 of Maddon et al. instead of lysine was the result of a sequenc¬ ing error (Dr. Richard Axel, personal communication). The significance of the amino acid replacements at positions 64 and 231, which may represent allellic polymorphism [T. C. Fuller et al., Human Immunology, 9, pp. 89-102 (1982); W. Stohl and H. G. Kunkel, Scand. J. Immunol., 20, pp. 273-78 (1984); N. Amino et al., Lancet, 2, pp. 94-95 (1984); and M. Sato et al., J. Immunol., 132, pp. 1071-73 (1984)], is not known. DNA sequence analysis [Maxam and Gilbert, supra] of the insert in pEClOO of the REX clone sug¬ gests that it represents the product of a splicing error, because 5' noncoding sequence appears to have been spliced with coding sequence beginning with the GGT codon for glycine (amino acid 49) (see Figure 3 and Figure 5). The T4 coding sequence in pEClOO* from glycine (amino acid 49) to isoleucine (amino acid 435) is identical to the sequence of Maddon et al. , (1985), supra. In comparison, our earlier N-terminal pro¬ tein sequence analysis of native T4 protein purified from U937 cells shows a T4 expression product with aspargine as amino acid 3. These differences are also set forth in Figure 6, which also depicts com- parisons at corresponding positions of the partial clone from the REX cell line λgtlO library; our * We constructed pEClOO by digesting the incomplete T4 cDNA clone from the REX library with EcoRI and isolating the 1,200 bp cDNA insert. We then ligated it to pUC12 (Boehringer Mannheim, Indianapolis, Indiana) which had been previously cut with EcoRI to form pEClOO. genomic clone from a λEMBL3 library; mouse T4 sequences [Tourvieille et al., Science, 234, p. 610 (1986)] and sheep T4 sequences [Classon et al., Immunogenetics, 23, p. 129 (1986)]. Construction of Soluble T4 Mutants We then employed the technique of in vitro site-directed mutagenesis and restriction fragment substitution to modify the T4 cDNA coding sequence of p!70-2 in sequential steps to be identical to that reported by Maddon et al. , (1985), supra. We first used oligonucleotide-directed mutagenesis to modify the amino acids at positions 3 and 64. Next, we employed restriction fragment substitution with a fragment including the serine 231 codon of a partial T4 cDNA isolated from a T4 positive lymphocyte cell line [O. Acuto et al., Cell, 34, pp. 717-26 (1983)] library in λgtll (a gift from Dr. Ellis Reinherz), to modify the amino acid at position 231. We then truncated our modified T4 cDNA sequence to remove the coding regions for the transmembrane and intra- cytoplasmic domains. Subsequently, we constructed three different soluble T4 mutants from our full length T4 clone PBL T4 by linker insertion between restriction sites in order to increase the probability of empirically finding a stable, secretable T4 mole¬ cule. The structure of each of these mutants is depicted in Figure 7A. Line A of Figure 7A represents a hydropathy analysis of our full length soluble T4 carried out using a computer program called Pepplot (University of Wisconsin Genetics Computer Group) according to J. Kyte and R. F. Doolittle, J. Mol. Biol., 157, pp. 105-32 (1982). Line B depicts the protein domain structure of full length T4 [Maddon et al., (1985) supra] in which "S" represents the secretory signal sequence, "V" represents the immunoglobulin-like variable region sequence, "J" represents the immuno- globulin-like joining region sequence, "U" represents the unique, extracellular region sequence, "TM" represents the transmembrane sequence and "C" repre- sents the cytoplasmic region sequence. In line B, the transmembrane amino acid sequence and some flank¬ ing sequence is written below the TM domain. Line C depicts the protein domain structure of recombinant soluble T4 mutants rsT4.1 in pBG377, rsT4.2 in pBG380 and rsT4.3 in pBG381. Line D represents the protein domain structure of E.coli rsT4 gene (Met-perfect construct) (pl99-7) which is deleted for the T4 N-terminal signal sequence (S). We constructed the first three soluble T4 mutant gene fragments by truncating our full length soluble T4 cDNA at positions corresponding to either intron/exon boundaries or to protein domain boundaries defined by hydropathy analysis predictions. More specifically, we introduced synthetic linkers into the unique Aval site that is 5' to the transmembrane/ extracellular domain boundary to produce an in-frame translational stop codon, thus constructing T4 genes that lack the transmembrane and cytoplasmic domains of the full length T4 sequence. For example, mutant rsT4.1 in pBG377 was truncated by the insertion of a stop codon following amino acid 362, lysine, which corresponds to the position of an intron separating the extracellular and transmembrane domain exons. The positions both of this intron and of the adjacent intron that splits the transmembrane and cytoplasmic domains were deter¬ mined by DNA sequence analysis of chromosomal T4 clones isolated from the λEMBL3 genomic library described above. Although the significance of the intron positions flanking the T4 transmembrane domain is not known, the determination of the genetic struc¬ ture could provide important information for design- ing rsT4 mutants, since exons frequently define functional domains [W. Gilbert, "Why Genes In Pieces?", Nature, 271, p. 501 (1978)]. We then constructed mutant rsT4.2 in pBG380 by truncating the T4 cDNA at the boundary of the transmembrane and extracellular domains at amino acid 374. And, we constructed mutant rsT4.3 in pBG381 by truncating the T4 cDNA at amino acid 377, three amino acids downstream from the transmembrane/ extracellular domain boundary and within the trans¬ membrane domain. We also employed the technique of oligo¬ nucleotide site directed mutagenesis, according to D. Strauss et al., "Active Site Of Triosephosphate Isomerase: In Vitro Mutagenesis And Characterization Of An Altered Enzyme", Proc. Natl. Acad. Sci. USA, 82, pp. 2272-76 (1985), to construct a fourth soluble T4 mutant from our full length T4 clone PBL T4. The structure of this mutant is depicted in Figure 7A, line D, which represents the protein domain structure of E.coli rsT4 gene (Met-perfect rsT4.2) construct, deposited in pl99-7, which is deleted for the T4 N-terminal signal sequence (S). We also constructed various other soluble T4 deletion mutants to determine which smaller fragments of the T4 sequence provide a protein which binds to HIV. These constructions were based on our belief that only the amino terminal sequence of T4 is required for binding to HIV. This belief, in turn, was based upon observations that the monoclonal anti¬ body 0KT4A blocks infection of T4 positive cells by HIV and it appears to recognize an epitope in the amino portion of T4 [Fuller et al. , supra] . Such fragments of T4, which lack glycosylation and which are capable of binding HIV and blocking infection, may be produced in E.coli or chemically synthesized. The structure of each of these deletion mutants is depicted in Figure 7B. In that figure, line A depicts the protein domain structure of full length T4 [Maddon et al. , (1985), supra; Figure 7A] . In line B, the protein structure of recombinant soluble T4 mutants are depicted as follows: rsT4.7 in p203-5, rsT4.7 in pBG392, rsT4.8 in pBG393, rsT4.9 in pBG394, rsT4.10 in pBG395, rsT4.11 in pBG397, rsT4.12 in pBG396, rsT4.111 in pBG215-7, rsT4.113.1 in PBG211-11 and rsT4.113.2 in pBG214-10. We constructed soluble T4 derivatives p203-5, pBG392, pBG393, pBG394 and pBG396 by trun¬ cating our rsT4.2 gene after the StuI sites at amino acids 183 and 264 of rsT4.2. More specifically, we constructed derivative rsT4.7 in p203-5 and in pBG392 by truncating the rsT4.2 cDNA at amino acid 182. And, we constructed each of derivatives rsT4.9 in pBG394 and rsT4.12 in pBG396 by truncating the rsT4.2 cDNA at amino acids 113, and 166, respectively. One may also construct each of derivatives rsT4.10 in pBG395 and rsT4.11 in pBG397 by truncating the rsT4.2 cDNA at amino acids 131 and 145, respectively. Expression of T4 and Soluble T4 Polypeptides In Bacterial. Cells The cDNA sequences of this invention can be used to transform eukaryotic and prokaryotic host cells by techniques well known in the art to produce recombinant soluble T4 polypeptides in clinically and commercially useful amounts. For example, we constructed expression vector pl99-7, as shown in Figure 9A, as follows. We preceded the construction depicted in Figure 9A by the construction of various intermediate plasmids, as depicted in Figures 8A-8D. Those con- structions were carried out using conventional recombinant techniques. The linkers employed in those constructions are set forth in Figure 10. As depicted in Figures 8A and 8B, starting with pl70-2, which contains our full length T4 DNA sequence, coding for T4 characterized by three dif¬ ferent amino acids than that of Maddon et al. , (1985), supra, we produced various constructs which direct the expression of soluble T4. Some of these con¬ structs are characterized in that one or more of those amino acid differences have been changed to correspond to the respective amino acids of Maddon et al. In this figure, as well as in the other figures, amino acid changes are reflected by an arrow. Plasmid pl92-6 contains the Met perfect rsT4.2 sequence derived by oligonucleotide site- directed mutagenesis which removed the entire T4 N-terminal signal sequence as shown in Figure 8C. And, to provide a convenient means of transferring the rsT4.2 Met perfect sequence into E.coli expression vectors, the steps described in Figure 8D were carried out to produce pl95-8, a plasmid containing the Met perfect rsT4.2 sequence flanked by Clal restriction sites. The Clal-Clal cassette of pl95-8 optimizes the distance between the 5' Clal site and the initiating Met codon. In Figure 8D, ST8 rop " is a tetracycline resistance encoding pAT153- based plasmid containing the rop " mutation that permits high plasmid copy number, a promoter and ribosome binding site from bacteriophage gene 32 and the gene 32 transcription termination sequence. Cleavage of pl95-8 with Clal produced the fragment used to assemble pl99-7, a construction which directs the expression of Met perfect rsT4.2 under the control of the P_ promoter (Figure 9A) . As the first step, to construct a vector from which rsT4.2 expression is under control of the P r Li promoter, we constructed the vector pl97-12 from pl034 (plmuGCSF) (Figure 9A). We then cut pl034 with EcoRI and BamHI to excise the GCSF cDNA insert and a portion of the phage u ribosome binding site sequence — which we subsequently reconstructed with oligonucleotides. The synthetic linkers used were linkers 57-60 (Figure 10). We then ligated the synthetic linker into the EcoRI/BamHI-cut pl034 to form pl97-12. One could, instead, replace these steps by starting with any suitable E.coli expression vector containing a Clal site appropriately placed between the promoter and terminator sequences. We cut pl97-12 with Clal and inserted a Clal-Clal cassette containing the cDNA sequence of rsT4.3 in pBG381 and phage transcription terminator derived from pl034. The sequence of this cassette is depicted in Figure 11. The resulting plasmid, pl99-7, contains the rsT4.2 "Met perfect" gene in that vector. Alternatively, one could derive the Met perfect rsT4;2 sequence from plasmid pBG380, deposited in connection with this application, and gap out the signal sequence to create pl92-6. We tested for expression of pl99-7 as follows. SG936, an E.coli Ion htpr double mutant [ATCC 39624] [S. Goff and A. Goldberg, "ATP-Dependent Protein Degradation In E.coli", in Maximizing Gene Expression, W. Reznikoff and L. Gold (eds.) (1986)], was transformed with pl99-7 by conventional proce¬ dures [Maniatis et al. (1982)] to form SG936/pl99-7, a transformant containing a plasmid with the Met- perfect rsT4.2 gene behind the P- promoter. Trans- formants were selected on LB agar plates containing 10 mcg/ml tetracycline (tet). After streaking out several single colonies for single colony isolation, one was chosen at random for testing induction of rsT4.2 synthesis. We picked a single colony from an LB-agar tet + plate into 20 ml Luria Broth (LB) and 10 mcg/ml tet in a 125 ml shake flask and grew it overnight in a shaking air incubator (New Brunswick Scientific, New Jersey) at 30°C. We then initiated an induction culture by adding 0.5 ml of the overnight culture to 50 ml LB and tet in a 500 ml flask which was grown at 30°C in a shaking air incubator. When the culture reached an OD(600) of 0.4, we transferred it to a 42°C water- bath and shook it gently for approximately 20 minutes. After heat induction at 42°C, the flask was trans¬ ferred to a 39°C air incubator (New Brunswick Scientific, New Jersey) where it was shaken vigorously at 250 rpm. We withdrew samples just after the 42°C heat shock, and at hourly time points for 4 hours, and then after overnight growth. The samples were measured for growth by OD(600) and analyzed following SDS-PAGE for the pattern of protein synthesis by Coomassie blue protein staining and by Western blot analysis with our rabbit antipeptide antibody probes (described above). Based on the relative molecular weight and protein blot analysis, the expression of rsT4.2 was induced from SG936/pl99-7 following heat induction at 42°C (Figure 12). We transformed pl99-7 into a P τ mu.tet expression vector, an E.coli expression vector, at the unique Clal site (see Figure 11). The nucleo¬ tide and amino acid sequences of pl99-7 are shown in Figure 11. The expression of soluble T4 from pl99-7 in E.coli was measured by Western blot analysis of whole cell extracts following SDS-PAGE using the rabbit polyclonal anti-peptide JB-1 or anti-peptide JB-2 antibodies as probes (Figure 12). We also constructed expression vector p203-5, as shown in Figure 9B, as follows. We started with pl97-7, which has the same sequence as the P L um vector pl97-12 (see Figure 9A), except that there is a single nucleotide deletion in the 5' noncoding region following the P. promoter. That deletion, which is a deletion of nucleotide #40 — adenine — of pl97-12 (see Figure 11), resulted from a deletion in the region that was constructed from linkers 57-60 (see Figure 10). pl97-7 contains the rsT4.2 gene comprising 374 amino acids. Alter- natively, one could also use pl97-7 as a starting plasmid. We cut pl97-7 with Clal. We also cut pl95-8 (see Figures 8D and 9A) with Clal to remove the Clal - Clal cassette containing the cDNA sequence of rsT4.2. Subsequently, we inserted the Clal-Clal cassette into pl97-7 to produce pl98-2. We then digested pl98-2 with StuI to remove 80 amino acids (amino acid 185 to amino acid 264) of the mature T4 protein coding sequence. Unex- pected methylation, however, prevented cutting at the second StuI site, so that only the StuI site at amino acid 184 was cleaved. Following ligation, the plasmid DNA was transformed into E.coli and we examined several plasmid clones for the deletion using standard procedures. None of those plasmids contained the expected StuI deletion. Subsequent DNA sequence analysis of one of these plasmids, called p203-5, showed that two guanine residues (see amino acids 183 and 184; nucleotides 818 and 819 of Figure 3) of the StuI recognition sequence had been deleted following cleavage due to exonuclease digestion caused by the use of exonuclease-contaminated StuI enzyme. This dinucleotide deletion produced a translation frame- shift following amino acid 182 (glutamine) and intro¬ duced a stop codon six amino acid codons downstream from the frameshift (Figure 9C). The unexpected methylation of the second StuI site together with the deletion that resulted in a new stop codon produced a gene encoding a shortened form of recom¬ binant soluble T4, called rsT4.7. The rsT4.7 sequence encodes a 182 amino acid N-terminal segment of the mature T4 sequence followed by, at the C-terminus, six amino acids — asparagine-leucine-glutamine- histidine-serine-leucine — of non-T4 sequence and finally by a TAA stop codon. The expression of soluble T4 from p203-5 in E.coli was measured by Western blot analysis as previously described. Expression of T4 and Soluble T4 Polypeptides In Animal Cells We inserted both soluble T4 genes and the unmodified gene encoding membrane-bound T4 into animal expression vector pBG368. More specifically, we inserted each of the soluble gene constructs into pBG368 under the transcriptional control of the adenovirus late promoter, to give plasmids pBG377, pBG380 and pBG381. We also made two pBG312-based constructions, called pBG378 and pBG379, which direct the expression of recombinant full length T4 protein. pBG378 and pBG379 code for the same full length T4 protein but in pBG379, a portion of the 3' untranslated sequence has been removed. Subsequently, to test for expression of recombinant soluble T4 and recombinant full length T4, we cotransfected Chinese hamster ovary ("CHO") cells with one of each of those plasmids and with the plasmid pAdD26. We first constructed pBG368 as follows. As depicted in Figure 13, we cut animal cell expres¬ sion vector pBG312 [R. Cate et al., "Isolation Of The Bovine And Human Genes For Mullerian Inhibiting Substance And Expression Of The Human Gene In Animal Cells", Cell, 45, pp. 685-98 (1986)] with EcoRI and Bglll to delete one of each of the two EcoRI and the two Bglll restriction sites (the EcoRI site at posi¬ tion 0 and the Bglll site located at approximately position 99). The resulting plasmid, pBG368, retained an EcoRI site in the cloning region and a Bglll site after the cloning region. This left a single EcoRI site and a single Bglll site in the polylinker for cloning purposes. More specifically, we deleted one EcoRI site and one Bglll site by sequential partial diges¬ tion of pBG312 with restriction enzymes EcoRI and Bglll, respectively. We filled in with Klenow and 4 nucleotides then religated to produce pBG368, which contains unique restriction sites for EcoRI and Bglll enzymes. Once transient expression of soluble T4 was verified, we constructed stable cell lines that continuously expressed soluble T4. To do this, we employed the stable cell expression host, the dihydrofolate reductase deletion mutant (DHFR~) Chinese hamster ovary cell line [F. Kao et al., "Genetics Of Somatic Mammalian Cells X Complementation Analysis of Glycine-Requiring Mutants", Proc. Natl. Acad. Sci., 64, pp. 1284-91 (1969); L. Chasin and G. Urlab "Isolation Of Chinese Hamster Cell Mutants Deficient In Dihydrofolate Reductase Activity", Proc. Natl. Acad. Sci., 77, pp. 4216-80 (1980)]. Using this system, we cotransfected each T4 gene construct with pAdD26 [R. J. Kaufman and P. A. Sharp, "Amplification And Expression Of Sequences Cotransfected With a Modular Dihydrofolate Reductase Complementary DNA Gene", J. Mol. Biol . , 159, pp. 661-21 (1982) containing the mouse DHFR gene. Before carrying out the co-transfections, we linearized all plasmids by restriction enzyme cleavage and, prior to transfection, we mixed each plasmid with pAdD26 so that the molar ratio of pAdD26 to T4 was 1:10. This maximized the number of T4 gene copies per transfeetant. Within the cell, the plasmids were ligated together to form polymers that can become integrated into host chromosomal sequences by illegitimate recombination [J. Haynes and C. Weissmann, "Constitu¬ tive, Long-Term Production Of Human Interferons By Hamster Cells Containing Multiple Copies Of a Cloned Interferon Gene", Nucl. Acids Res. , 11, pp. 687-706 (1983); S. J. Scahill et al., "Expression And Charac¬ terization Of The Product Of A Human Immune Interferon cDNA Gene In Chinese Hamster Ovary Cells", Proc. Natl. Acad. Sci. USA, 80, pp. 4654-58 (1983)]. We selected transfectants that express the mouse DHFR gene in culture medium lacking nucleotides. We then subjected these transfectants to a series of increasing concen¬ trations of methotrexate, a toxic folate analogue that binds DHFR, to select for cells levels of DHFR. Resistance to methotrexate by increased expression of DHFR is frequently the result of DHFR gene amplification, which can include the reiteration of large chromosomal segments, called amplified units [R. J. Kaufman and P. A. Sharp, "Amplification And Expression Of Loss Of Dihydrofolate Reductase Genes In A Chinese Hamster Ovary Cell Line", Molec. Cell. Biol., 1, pp. 1069-76 (1981)]. Therefore, cointegration of DHFR and rsT4 sequences permitted the amplification of rsT4 genes. Stably transfected cell lines were isolated by cloning in selective growth medium, then screened for T4 expression with a T4 antigen (RIA) [D. Klatzmann et al., Nature, 312, pp. 767-68 (1984)] and by immunoprecipitation from conditioned medium after [ 35S] cysteme (" 35S-Cys") metabolic labelling. We also inserted the soluble T4 derivative rsT4.7 gene into an animal cell expression plasmid as follows. As set forth in Figure 14C, we cut plasmid pBG381 (Figure 14A) with EcoRI and Nhel. We then cut pl86-6 with EcoRI and Nhel to remove the 786 base pair fragment. We ligated that fragment into the digested pBG381 to form plasmid pBG391. The T4 sequence in pBG391 is identical to both that of Maddon et al. (1985) supra at positions 64 (tryptophan) and 231 (phenylalanine) and to that of pBG381. How¬ ever, at position 3, the asparagine reported by Maddon et al. and present in pBG381 is replaced with lysine. The nucleotide sequence of pBG391 is depicted in Figure 15. We then digested p203-5 with Nhel and OxanI to remove the 483 base pair fragment. We inserted that fragment into Nhel/Oxanl-digested pBG391 to form plasmid pBG392, the animal cell ' expression construct of rsT4.7. The T4 sequence in rsT4.7 contains amino acids identical to that of Maddon et al. 's full length sequence at amino acid positions 64 (tryptophan) and 231 (phenylalanine) . However, at position 3, the asparagine reported by Maddon et al. is replaced with lysine. The nucleo¬ tide sequence of pBG392 is depicted in Figure 16. In Figure 14D, we have depicted the con- struction of other animal cell expression constructs containing sequences encoding the deletions rsT4.9 in pBG394, and rsT4.12 in pBG396. Those constructions were carried out using conventional recombinant tech¬ niques. The linkers employed in those constructions are set forth in Figure 18. The nucleotide sequences of pBG394 and pBG396 are shown in Figures 19 and 20. Plasmid pBG393, shown in Figure 17, con¬ tains rsT4.8, the perfect form of rsT4.7. pBG393 contains 182 amino acids of the mature T4 sequence, without the additional non-T4 6 amino acids at the C-terminus following amino acid 182. The nucleotide sequence of BG393 is shown in Figure 21. Other animal cell expression plasmids according to this invention may be constructed as depicted in Figure 17. These include rsT4.10 in pBG395 and rsT4.11 in pBG397 (see Figure 18 for specific linkers). The nucleotide sequence of BG395 is shown in Figure 22. Purification Of Recombinant Soluble T4 Recombinant soluble T4 construct pBG380 expressed in DHFR- CHO cells was grown to confluency in a α-Modified Eagles Medium (Gibco) supplemented with 10% fetal calf serum, 1 mM glutamine and the antibiotics penicillin and streptomycin (100 μg/ml of each). The cells were grown at 37°C in two 21 Cell Factory Systems (Nunc). We then washed the confluent cells free of fetal calf serum with α-Modified 'Eagles Medium without fetal calf serum and cultured the cells in α-Modified Eagles Medium at 37°C for 4 days. Subsequently, we harvested the conditioned media, filtered it through a Millipore Minidisk 0.22μ hydrophilic filter cartridge (Millipore #MCGL 305-01) and concentrated the secreted proteins on a fast-S ion exchange column (S-Sepharose Fast Flow, Pharmacia #17-0511-01) in 20 mM MES buffer (pH 5.5). We then eluted the bound proteins with 20 mM Tris-HCl (pH 7.7) and 0.3 M NaCl. The elution pool was subsequently diluted with 2 volumes of 20 mM Tris-HCl (pH 7.7) and it was then loaded on a column comprising immobilized 19Thy anti-T4 monoclonal anti- body coupled to Affigel-10 [a gift of Dr. Ellis Reinherz, Dana Farber Cancer Institute, Boston, Massachusetts] . We washed the column extensively and eluted the bound material as 0.5 ml fractions with 50 mM glycine-HCl (pH 2.5), 150 mM NaCl, 0.1 mM EGTA and 5 μg/ml bovine pancreatic trypsin inhibitor, Aprotinin (Sigma #A1153). We used Western blots developed with rabbit antisera raised against peptide JB-2 to follow the purification. We employed silver stained gels to follow binding and elution of rsT4.2 during the chromatography. Figure 23 depicts a Coomassie stained gel of purified rsT4.2. Gel sizing-column chromatography analysis of the purified rsT4.2 from the pBG380 transfected CHO cell line, BG380G, suggests that rsT4 is monmeric under physiologic pH and salt concentration. Sequencing Of Recombinant Soluble T4 Protein We then determined the N-terminal amino acid sequence of a recombinant soluble T4, specifi¬ cally rsT4.2, molecule purified from the conditioned medium of the pBG380 transfected CHO cell line BG80G, as described above, by automated Edman degradation in an Applied Biosystems 47OA gas phase sequenator [R. B. Pepinsky et al., J. Biol Chem. , 261, pp. 4239-46 (1986)]. The amino terminal sequence matched the sequence which we had previously determined for solubilized native T4 isolated from U937 cells, supra. The amino terminal sequences of native solubilized T4 (sT4) and purified rsT4 protein are Δ2 proteins, as compared to the amino terminal sequence predicted by Maddon et al., (1985), supra, with the mature amino terminus located at position 3 of that sequence. The amino terminal sequences of solubilized native T4 (sT4), recombinant soluble T4 (rsT4.2) secreted by CHO transfectant BG380G containing pBG380 and the protein sequence deduced by Maddon et al. (1985), supra are as follows: ST4: X-K-V-V-L-X-K-K-X-D-T-V-E-L-T-X-T-A-S-E- rsT4.2: N-K-V-V-L-G-K-K-G-D-T-V-E-L-T-X-T-A-S-E- Maddon et al . -G-N-K-V-V-L-G-K-K-G-D-T-V-E-L-T-C-T-A-S-E In the above sequences, the amino acids are represented by single letter codes as follows: X: not determined or ambiguous. We also constructed pBG211-ll, a plasmid coding for the N-terminal 113 amino acids of soluble T4 protein. This construct, which codes for a pro¬ tein characterized by a single disulfide bridge, between the cysteines at amino acid positions 18 and 86, is conveniently expressed in E.coli. To construct p211-ll, as depicted in Fig¬ ure 24, we first cut pl95-8 (see Figures 8D and 9A) with Clal to remove the Clal-Clal cassette contain- ing the cDNA sequence of rsT4.2. We then digested pAT153γ3SH16ΔAmp, the tryptophan operon promoter plasmid from the gamma interferon producing E.coli strain BN374 with Clal, and deleted the cDNA coding for gamma interferon. Subsequently, we inserted the Clal-Clal cassette into the Clal-cut E.coli plasmid in front of the tryptophan operon promoter and ligated to produce pl96-10. As shown in Figure 25, we then subjected pBG380 to oligonucleotide-directed mutagenesis to insert three tandem translational stop codons follow¬ ing the T4 cDNA sequence coding for amino acids -23 to 113 in pBG380, co produce pBG394. We then constructed. p211-ll from fragments of each of pl96-10, pBG394 and pl034 as depicted in Figure 26. The first fragment including the vector sequences, was produced by restricting pl96-10 with Hindlϊl and Clal to remove the T4 coding sequence from amino acids 61 through 374 of rsT4.2 and includ¬ ing vector sequence following the 3' end of the rsT4 gene. The second fragment, a HindiII - Bglll segment including the codons for T4 amino acids 61-113 of rsT4.9 immediately followed by a triplet of stop codons in tandem, was isolated by Hindlll/Bglll diges¬ tion of pBG394. The third fragment, a BamHI - Clal fragment containing a bacteriophage T4 transcriptional termination signal [H. N. Kirsch and B. Allet, "Nucleotide Sequences Involved In Bacteriophage T4 Gene 32 Translational Self-Regulation", Proc. Natl. Acad. Sci. USA, 79, pp. 4937-41 (1982)], was isolated by BamHI/Clal digestion of pl034. We then ligated these three fragments to produce p211-ll, a T4 con¬ struct coding for a 113 amino acid soluble form of T4 protein, with asparagine at amino acid position 3 (i.e. , rsT4.113.1). We then subjected p211-ll to oligonucleo- tide site-directed mutagenesis (Figure 27) to change the amino acid at position 3 from asparagine to lysine using the oligonucleotide T4-66: GGC 3' . This produced plasmid p214-10, a fully corrected 113 amino acid soluble T4 vector coding for a 113 amino acid soluble form of T4 protein, with lysine at amino acid position 3 (i.e., rsT4.113.2). As shown in Figure 27, we subjected p214-10 to oligonucleotide site-directed mutagene¬ sis to delete glutamine and glycine at, respectively, amino acid positions 1 and 2 of the T4 sequence using the oligonucleotide T4AID-87: ATG ATG AAA AAA GTA GTA 3' . This produced p215-7, a 111 amino acid soluble T4 construct, including the trp promoter, which directs the expression of a 111 amino acid soluble form of T4 protein, with lysine at amino acid position 3 (i.e., rsT4.111). We next constructed p218-8, a 111 amino acid construct which directs the expression of a 111 amino acid soluble form of T4 protein, with lysine at amino acid position 3 (i.e., rsT4.111) under the control of the P_ promoter, as depicted in Figure 28. More specifically, we cut pl97-12 (-Figure 9A) with Clal to remove the 101 bp fragment contain¬ ing linker and terminator sequences. We also cut p215-7 with Clal to remove the Clal - Clal cassette containing the cDNA sequence of rsT4.111 and the φT4 transcriptional terminator sequence [Kirsch and Allet, supra] . Subsequently, we inserted the Clal - Clal cassette into the Clal-cut pl97-12 to produce p218-8. In order to express rsT4.113.1, we trans¬ formed E.coli A89 with p211-ll by conventional techniques [Maniatis et al. (1982), supra] to form E.coli A89/p211-ll. E.coli A89 is a tetracycline sensitive derivative of E.coli SG936. We isolated E.coli A89 from E.coli SG936 according to the method of S. R. Maloy and W. D. Nunn, "Selection For Loss Of Tetracycline Resistance By Escherichia coli", J. Bact., 145, pp. 110-12 (1981), which is based upon the ability of the lipophilic chelating agent fusaric acid to selectively inhibit resistant strains. More specifically, we plated E.coli SG936 on medium containing, per liter, 5 g tryptone, 5 g yeast extract, 10 g NaCl, 10 g NaH 2 P0 4 « H 2 0, 50 mg chlortetracycline- HC1, 12 mg fusaric acid, 0.1 mM ZnCl 2 and 15 g agar. Colonies which grew at 30°C (putative tetracycline- sensitive strains) were retested for tetracycline sensitivity on L-agar plates containing 5 μg/ml tetracycline. One tetracycline-sensitive strain, designated A89, was then shown to be unable to grow on LB agar at 42°C, thus verifying the presence of the htpR mutation. Transformants were selected by tetracycline resistance. We picked a single colony into 20 ml of minimal medium plus 0.2% casamino acids plus trypto- phan (100 μg/ml) plus tetracycline (10 μg/ml) in a 100 ml shake flask placed in a shaking air incubator at 30°C and allowed the cells to grow up overnight. The following morning, we inoculated 40 ml of mini¬ mal medium plus 0.2% casamino acids plus tryptophan (100 μg/ml) plus tetracycline (10 μg/ml) with the overnight culture at OD gQO = 0.05 in a 500 ml flask. The cells were grown to midlog phase and then induced by pelleting, washing once in minimal medium and then resuspending in minimal medium plus 0.2% cas- amino acids plus tetracycline (10 μg/ml), in the absence of tryptophan. We removed 0.6 OD &00 of cells after 0, 1, 2, 3 and 4 hours incubation and after growth overnight. The aliquots were centrifuged and cell pellets were subjected to lysis by boiling in Laemmli gel loading buffer. After centrifugation to remove cell debris, half of each sample was subjected to SDS-PAGE, followed by Western blot analysis with our rabbit antipeptide antibody probes or by Coomassie blue protein staining (Figures 29A and 29B). Purification Of rsT4.113.1 We then purified rsT4.113.1 from the E.coli transformant by means of two essentially quantitative steps involving anion-exchange and gel-filtration chromatographies performed under reducing and dena¬ turing conditions. More specifically, we suspended 14 g of wet cells from a 4 L shake-flask fermentation in 100 ml of a 20mM Tris (pH 7.5) buffer containing 20 μg/ml DNase, 20 μg/ml RNase and 1 mM phenylmethyl- sulfonylfluoride ("PMSF"). The suspension was applied to a French Press at 1000 psi in two passages and then centrifuged in an SA 600 rotor at 18,000 g for 15 min at 4°C. The resulting pellet was solubilized in 20 ml of a 20 mM Tris (pH 7.5) buffer containing 7 M urea and 10 mM 2-mercaptoethanol. We then sub¬ jected the suspension to ultracentrifugation at 85,000 g for 90 min at 4°C. The supernatant was diluted by the addition of 80 ml of 20 mM Tris (pH 7.5) buffer containing 7 M urea and 10 mM 2-mercaptoethanol and 40 ml of the sample was applied to a 3 x 4 cm Q-Sepharose fast-flow column (Sigma, St. Louis, Missouri) which had been pre- equilibrated in the same buffer. The column was developed with a gradient in 400 ml total volume of increasing NaCl from 0 to 0.3 M in the same Tris/urea/ 2-mercaptoethanol buffer. Column fractions were monitored for absorbance at 280 nm and for protein content by SDS-PAGE (15% acrylamide). The fractions were also analyzed by Western blots. Figure 30, panel (a) is a chromatogram displaying the purifi¬ cation of rsT4.113.1 by ion-exchange chromatography. In that figure, peaks containing rsT4.113.1 are identified. The rsT4.113.1 was found to elute early in the NaCl gradient and to be well-resolved from low-molecular weight contaminants. In order to separate rsT4.113.1 from high- molecular weight contaminants, we carried out gel- filtration chromatography on an rsT4.113.1-containing pool for final purification of the protein to near homogeneity (>95% purity). More specifically, we prepared a pool containing 20 mg of protein in 50 ml and then concentrated to 10 ml in a stirred-cell ultrafiltration unit (Amicon, Danvers, MA.) using a PM-30 membrane (Amicon). Subsequently, 5.0 ml of the concentrate was applied to a 1.5 x 95 cm S-300 column (Sigma) equilibrated and developed in the same Tris/urea/2-mercaptoethanol buffer. We moni¬ tored the column fractions for absorbance at 280 nm and for protein content by SDS-PAGE. The fractions were also analyzed by Western blots. A pool con¬ taining rsT4.113.1 (approximately 4 mg) in 15 ml was thus prepared. Figure 30, panel (b) is a chromato- gram displaying the purification of rsT4.113.1 by gel-filtration separation of the rsT4.113.1 pool. In that figure, peaks containing rsT4.113.1 are identified. Figure 30, panel (c) is an SDS-PAGE analysis depicting the purification of the rsT4 derivative throughout the centrifugation and chromatography steps. In Figure 30, panel (c), the lanes depicted are: lane A: molecular weight standards lane B: cell extracts lane C: cell pellet following solubilization of cell extract in non-denaturing conditions lane D: supernatant following solubilization of cell extract in non-denaturing buffer lane E: supernatant following ultracentri- fugation step lane F: -Sepharose pool lane G: S-300 gel-filtration pool. Refolding Of Purified rsT4.113.1 We refolded the purified rsT4.113.1 by dilution and dialysis steps to non-denaturing and oxidized conditions. More specifically, refolding of the protein at a concentration of 0.5 OD (280)/ml was achieved by stepwise dialysis against 500 volumes of 3 M urea, 20 mM Tris (pH 7.5); 500 volumes of 1 M urea, 0.1 M ammonium acetate (pH 6.8) and, finally, the same volume of a phosphate-buffered saline solu¬ tion. Throughout the refolding procedure, samples of the protein were monitored for relative content by spectral analysis and by high-performance liquid chromatography ("HPLC") performed on a 150A liquid chromatographic system (Applied Biosystems, Inc., Foster City, California). An octasilyl column (Aquapore RP-300, 0.46 x 3.0 cm) was equilibrated in 80% 0.1% trifluoroacetic acid ("TFA")/water (sol- vent A) and 20% 0.085% TFA/70% acetonitrile (sol¬ vent B) and developed with a linear gradient of increasing acetonitrile concentration from 20% to 80% (solvent B) over 45 min at a flow rate of 0.5 ml/min. As shown in Figure 31, panel (a), protein in 7 M urea, 10 mM 2-mercaptoethanol and 20 mM Tris(pH 7.5) eluted from the HPLC column at 49% acetonitrile in the gradient. In subsequent steps, from 1 M urea/1 mM ammonium acetate (pH 6.8) [Fig- ure 31, panel (b)] to phosphate buffered saline [Figure 31, panel (c)], an increasing percentage of rsT4.113.1 was found to elute earlier in the HPLC gradient — at 47% acetonitrile. The identity of the earlier eluting peak as oxidized product was verified by reduction of rsT4.113.1 in non-chaotropic solutions and application of sample thus treated to HPLC under the same conditions. The elution of oxidized rsT4.113.1 prior to reduced protein on HPLC suggests that formation of the single disulfide bridge decreases relative hydro- phobicity of the protein [J. L. Browing et al., Anal. Biochem. , 155, pp. 123-28 (1986)]. Spectral analysis of rsT4.113.1 was performed throughout the course of refolding in order to monitor relative yield of solu- ble protein in the procedure. The refolding method allowed approximately 20% recovery of rsT4.113.1. HPLC analysis indicated a less than 15% contaminant of reduced protein in the preparation (Figure 30, panel (c), lane G). Sequencing Of Renatured rsT4.113 We then carried out amino acid analysis of rsT4.113.1 by automated Edman degradation in an Applied Biosystems 470A gas phase sequenator equipped with a 900 A data system. Phenylthiohydantion amino acids generated during the course of the degradative chemistry were analyzed on-line using an Applied Biosystems 120A PTH-analyzer equipped with a PTH-C18 2.1 x 220 mm column. Protein (10 μg) for sequence analysis was applied to SDS-PAGE (15% acrylamide) and electroblotted on an Immobilon membrane (Millipore Corp., Bedford. Massachusetts) as described by P. Matsudaira, J. Biol. Chem., 262, pp. 10035-38 (1987). Amino acid analysis of protein samples was performed by hydrolysis of protein in 6 N HCl, in vacuo, for 24 h at 110°C. The hydrolysates were then applied to a Beckman 6300 Analyzer equipped with post-column detection by ninhydrin. Western blot analysis of the SDS-PAGE gels was carried out by standard techniques using rabbit antisera JB-1. Sequence analysis revealed an amino terminal sequence of: Met-Gln-Gly-Asn-Lys-Val-Val — The purified rsT4.113.1 protein was found to contain stoichiometric quantities of the amino- terminal methionine placed in the protein construct for expression in E.coli and an intact polypeptide chain consistent with a sequence derived from the plasmid construction. Recovery of phenylthiohydan- toinyl-methionine at the first cycle of the degrada- tive chemistry was 60% consistent with routine initial yields obtained in the automated Edman. This obser¬ vation excludes the possibiity that a significant percentage of the rsT4.113.1 lacked the initiation methionine, i.e., the H 2 -methionine was not removed by expression of rsT4.113.1 in E.coli, or that sequence analysis was impaired by the presence of glutamine at the first cycle of the degradative chemistry. Sequence analysis was performed for 40 cycles and no evidence of lysine carbamylation was observed. Amino acid analysis displayed a close correlation of actual and theoretical values for amino acids, thus indicating the marked absence of proteolytic degradation in the course of expression, or purification, or both. Immunoprecipitation Of CHO Cell Lines Producing Soluble T4 We tested the conditioned media from 35S-Cys metabolically labelled CHO cells transfected with one of the T4 mutant constructs pBG377, pBG380, pBG381, the full length recombinant T4 construct pBG379, of this invention or vector only, to determine whether any produced a molecule recognized by the anti-T4 monoclonal antibody 19 Thy. To carry out this test, 7 we incubated about 10 CHO cells transfected with either pBG380, pBG381, pBG377, pBG379 or pBG312, for 5 hours at 37°C with 180 μCi/ml 35S-labelled cysteme [DuPont, New England Nuclear] in 4 ml RPMI cys " medium (Gibco). After labelling of the cells, 1 ml of fil¬ tered, conditioned media was made 0.5 mM with phenyl- methyl-sulphonyl fluoride and immunoprecipitated with 0KT4 and protein A Sepharose [P. H. Sayre and E. L. Reinherz, Eur. J. Immunol. , 15, pp. 291-95 (1985)]. Subsequently, we incubated media from the 35 S-labelled cells with 0KT4 (ATCC #CRL 8002). We then immuno-precipitated with protein A Sepharose and subjected the immuno-precipitates to SDS-PAGE under reducing conditions on 10% polyacrylamide gels [U. K. Laemmli, Nature, 227, pp. 680-85 (1980)]. Autoradiography was carried out with X-Omat X-ray film (Eastman Kodak). As shown in lanes 3-5 of Figure 32, both pBG380 (rsT4.2) and pBG381 (rsT4.3) directed the synthesis of a secreted, immune, 35S-labelled T4 protein that was recognized by the 0KT4 anti-T4 antibody. The immunoprecipitated truncated mole- cules migrated as 49 Kd proteins, a result consis¬ tent with their predicted molecular weights. In contrast, no soluble T4 antigen could be detected in the conditioned media of cell lines stably trans¬ fected with pBG377 (rsT4.1) or pBG379 (rflT4). Immunoprecipitation analysis of cellular extracts of cell lines transfected with pBG377 suggests that the rsT4.1 gene may be misfolded, which could account for a block in its secretion [M. J. Gething et al., Cell, 46, pp. 939-50 (1986)]. In Figure 32, the lanes represent the following: Lane 1: immunoprecipitation from condi¬ tioned medium of CHO cells stably co-transfected with vectors pBG312 and pAdD26. Lane 2: blank. Lanes 3 and 4: immunoprecipitation from conditioned medium of CHO cells stably co-transfected with pBG380 (rsT4.2) and pAdD26. Lanes 5 and 6: immunoprecipita¬ tion from conditioned medium of CHO cells stably co-transfected with pBG381 (rsT4.3) and pAdD26. Lane 7: immunoprecipitation from conditioned medium of CHO cells stably co-transfected with recombinant full length T4 (pBG379) and pAdD26. In Figure 32, the arrow indicates the predicted position of the soluble T4 from pBG380 or pBG381 relative to the migration of standard molecular weight markers. Immunoprecipitation Of COS 7 Cell Lines Producing Recombinant Soluble T4 We expressed recombinant soluble T4 derivatives pBG392, pBG393 and pBG394 in COS 7 cells by electroporation, essentially as described by G. Chu et al., "Electroporation For The Efficient Transfection Of Mammalian Cells With DNA", Nuc. Acids Res. , 15, pp. 1311-26 (1987). More specifi¬ cally, we introduced 20 μg closed circular plasmid DNA and 380 μg of carrier (sonicated salmon sperm 7 DNA) into 3 x 10 COS 7 cells. The cells were electroporated using a Gene Pulser (Biorad) set at 300 volts. Subsequently, we incubated the COS 7 cells in Dulbecco's Modified Eagle's Medium supple¬ mented with 10% fetal calf serum for 24 hours. We then harvested the conditioned media, filtered it through a Millipore Minidisk 0.22 μ hydrophilic filter cartridge (Millipore #MCGL 305-01) and concentrated the secreted proteins on a fast-S ion exchange column (S-Sepharose Fast Flow, Pharmacia #17-0511-01) in 20 mM MES buffer (pH 5.5). We then eluted the bound proteins with 20 mM Tris-HCl (pH 7.7) and 0.3 M NaCl. The elution pool was subsequently diluted with 2 volumes of 20 mM Tris-HCl (pH 7.7) and it was then loaded on a column comprising either 19Thy anti-T4 monoclonal antibody and protein A Sepharose or 0KT4A and protein A Sepharose. We washed the column extensively and eluted the bound material as 0.5 ml fractions with 50 mM glycine-ΞCl (pH 2.5), 150 mM NaCl, 0.1 mM EGTA and 5 μg/ml Bovine pancreatic trypsin inhibitor, Aprotinin (Sigma, #A1153). The immunoprecipitates were subjected to SDS PAGE (10% gel) followed by immunoblotting against rabbit antisera raised against peptide JB-1. We employed silver stained gels to follow binding and elution of rsT4 during chromatography. Figure 33 depicts an immunoblot analysis of transiently expressed pBG392 (rsT4.7) [lanes 10, 11]; pBG393 (rsT4.8) [lanes 4, 7, 8] and pBG394 (rsT4.9) [lane 5]. The standards are 50 ng purified rsT4.3 (lane 1); 150 ng purified rsT4.3 (lane 2) and 250 ng purified rsT4.3 (lane 3). The arrow indicates the expected position of migration of a protein with the relative molecular weight of rsT4.7: 21,000 daltons. The sample that was to be loaded into lane 4 was lost and lanes 6 and 9 are blank. As shown in lanes 10 and 11 of Figure 35, pBG392 (rsT4.7) directed the synthesis of a secreted, immune protein that was recognized by the anti-T4 antibodies 0KT4A and 19Thy. Lanes 4, 7 and 8 also demonstrate that pBG393 (rsT4.8) directed the synthesis of a secreted, immune protein that was recognized by 0KT4A and 19Thy. This analysis illustrates that rsT4.7 contains the 0KT4A epitope. It also suggests that the binding region for HIV envelope binding resides in the amino 182 terminal residues of T4. In contrast, no soluble T4 could be detected in the media of cell lines transfected with pBG394 (rsT4.9) [see lane 5]. Immunoprecipitation analysis of cellular extracts of cell lines transfected with pBG397, however, showed that rsT4.9 was recognized by 0KT4A. We believe that rsT4.9, a 113 amino acid construct, binds the HIV virus and that it represents a second generation soluble T4, one with only two cysteines and one of three disulfide bridges. Accordingly, rsT4.9 is easily produced in E.coli or yeast systems. Similarly, although no soluble T4 could be detected in the media of cell lines transfected with pBG396 (rsT4.12), analysis of cellular extracts of those cell lines showed that rsT4.12 was recognized by 0KT4A. Thus, rsT4.12 may also bind HIV virus. Radioimmunoassay And Epitope Analysis Of rsT4.113 In order to determine if the 113 fragment of rsT4 contained structural determinants for binding to 0KT4A, Leu-3A and 0KT4, we then carried out radioimmunoassay and epitope analysis of rsT4.113 using a competitive inhibition radioimmunoassay [C. J. Newby et al., "Solid-Phase Radioimmune Assays" in Handbook Of Experimental Immunology, D. M. Weir (Ed.), 1, pp. 34.1-34.8 (1986)]. As 0KT4A and Leu-3A block infectivity of HIV in vitro [Dalgleish et al., supra] and binding of T4 to gpl20/160 [McDougal et al. supra], this analysis served as a first approximation as to whether or not rsT4.113 contained structural elements for interaction with HIV. We first coated U-bottom 96 well microtiter plates (Falcon) with 50 μl/well goat-anti-mouse IgG (Hyclone Typing Kit, Logan, Utah) in PBS (pH 7.0) to a concentration of 50 μg/ml and incubated the plates overnight at 4°C. We then rinsed the plates with IX PBS and blotted them dry. The plates were then blocked by the addition of 100 μl/well of a IX PBS solution containing 5% bovine serum albumin for 1 hour at room temperature. We rinsed the plates with PBS, blotted dry and then spotted them with 50 μl of one of three antibody solutions containing either 0KT4 (10 μg/ml in block buffer); 0KT4A (500 ng/ml in block buffer) or Leu-3A (Becton- Dickinson) (500 ng/ml in block buffer). We let the plates stand for 2 hours at room temperature. We then washed the plates 3 times with a PBS/0.05% Tween-80 solution and 2 times with IX PBS and blotted them dry. In a separate plate, we titrated competitor samples of unlabeled rsT4.113.1 from 20 μg/ml and serially diluted twice (including no competitor con¬ trol), with final volumes in each well of 25 μl. The positive control for this assay was competition with unlabeled rsT4.3 (375 amino acids). We then added 25 μl of 125I-rsT4.3 containing 10,000 cpm/25 μl (prepared according to A. E. Bolton and W. M. Hunter, Radioimmunoassay And Related Methods, Chapter 2c). Subsequently, we spotted the entire 50 μl content of each well onto the assay plate con¬ taining each of the three antibody solutions and incubated for 2 h at room temperature. We then washed the plates 3 times with a PBS/0.5% Tween-80 solution and 2 times with IX PBS, blotted them dry and then counted the wells in a Beckman gamma counter for radioactivity. ■ As shown in Figure 34, rsT4.113.1 competes with 125I-rsT4.3 for absorption to an 0KT4A solid phase in a dose-dependent manner. Additionally, rsT4.113.1 competes with 125I-rsT4.3 for absorption to a Leu-3A solid phase in a dose-dependent manner. By comparison to unlabeled rsT4.3, rsT4.113.1 exhibits a molar affinity for those antibodies within a factor of 3. In the 0.4 to 25 μg/ml concentration range tested, rsT4.113 did not compete with radiolabelled rsT4.3 for binding to 0KT4. In a similar assay, we observed that rsT4.111 also competes with 125I-rsT4.3 for binding to 0KT4A and Leu-3A, but not to 0KT4 [Figures 35-37] . Based on these results, we believe that the epitopes for 0KT4A and Leu-3A are contained within the amino-terminal 113 amino acids of T4. We also believe that the epitope for 0KT4 binding is localized within the carboxy terminal of the T4 polypeptide. Accordingly, we believe that the gpl20- binding domain is localized within the amino terminal 113 or 111 amino acids of the T4 protein. Based on this belief, we synthesized various synthetic oligo¬ peptides which contain sequence within that structural domain. These oligopeptides are represented in Figure 3 as follows: Oligopeptide Amino Acid Coordinates JB-1 44-63 rsT4 #6 18-29 rsT4 #7 5-56 rsT4 #8 84-97 rsT4 #9 30-63 We synthesized these peptides using conventional phosphoamide DNA synthesis techniques [Tetrahedron Letters, 22, pp. 1859-62 (1981)]. We synthesized the peptides on an Applied Biosystems 380A DNA Synthesizer and- purified them by gel electrophoresis. ELISA Assay For rsT4.113 We also carried out an ELISA assay for rsT4.113.1 produced by p211-ll-transformed E.coli. Throughout this assay, dilutions were made in block¬ ing solution and, between each step, we washed the plates with PBS/0.05% Tween-20. More specifically, we coated wells of Immulon 2 (Dynatech, Chantilly, Virginia) plates with .005 OD (280 nm)/ml of 0KT4 (IgG2b) in 0.05 M bicarbonate buffer to a volume of 50 μl/well and incubated the plates overnight at 4°C. We then blocked the plates with 5% bovine serum albumin in PBS, 200 μl/well, and incubated for 30 minutes at room temperature. Subsequently, we added 50 μl of 50 ng/ml rsT4.3 to each well, incubating overnight at 4°C. We then added 50 μl/well of a mixture containing rsT4.113.1 and 10 ng/ml of 0KT4A and incubated for 2 1/2 hours at room temperature. Using a Hyclone Kit (Hyclone), we then carried out the following steps. First, we added 1 drop of rabbit anti-mouse IgG2a to each well and incubated the plates for 1 hour at room temperature. We then added 100 μl of peroxidase-labeled anti-rabbit IgG, diluted 1:4000 with blocking buffer to each well, and incubated for 1 hour at room temperature. We prepared a substrate reagent as follows. We diluted substrate reagent 1:10 in distilled water and added two O-phenyl-ethylene-diamine ("OPD") chromophore tablets per 10 ml of substrate. We let the mixture dissolve thoroughly by mixing with a vortex. Alternatively, a TMB peroxidase substrate system (Kirkegaard & Perry Catalogue #50-76-00) may be used. Subsequently, we added 100 μl of the chromophore solution to each well, incubated for 10-15 minutes at room temperature and then stopped the color development with 100 μl of IN H 2 S0 4 . We then measured OD at 490 nm, using an ELISA plate reader. The results of the assay are demonstrated in Figure 38. We then subjected the soluble T4 proteins produced by the T4 constructs of this invention to various functional assays. Assays Of The Antiviral Activity Of Soluble T4 The antiviral activity of soluble T4 according to this invention was evaluated using modifications of various in vitro systems used to study antiviral agents and neutralizing antibodies [D. D. Ho et al., "Recombinant Human Interferon Alpha (A) Suppresses HTLV-III Replication In. Vitro", Lancet, pp. 602-04 (1985); K. Hartshorn et al., "Synergistic Inhibition Of HTLV-III Replication In Vitro By Phosphonoformate And Recombinant Inter¬ feron Alpha-A", Antimicrob Ag Chemoth, 30, pp. 189-91 (1986)]. For each of these assays, we prepared graded concentrations of soluble T4 and preincubated them with an H9 derived IIIB isolate of HIV [a gift from Drs. M. Popovic and R. Gallo, National Cancer Institute, Bethesda, Maryland] . The isolate was maintained as a chronically infected culture in H9 cells. Cell-free HIV stocks were obtained from supernatant fluids of HTLV-III infected H9 cultures g (culture conditions: 1 x 10 cells/ml with 75% viable cells). We prepared serial 10 fold dilutions of recombinant soluble T4 ranging from 10 picograms/ml to 10 micrograms/ml and incubated them with fifty 50% tissue culture infectious doses (TCID 5Q ) of HIV for 1 hour at 37°C, in RPMI-1640 supplemented with 20% heat inactivated fetal calf serum (FCS). We then added 150 μl of H9 cells to a final concentra- g tion of 0.5 x 10 cells/ml which were not HIV-infected to the wells containing aliquots of the recombinant soluble T4/HIV mixture. We adjusted each virus inoculum to a con- centration of 250 TCID 50 /ml. We preincubated 100 μl of the virus inoculum with 200 μl recombinant solu¬ ble T4 or 100 μl immunoglobulin prepared in tripli¬ cate serial 2-fold dilutions for 1 hour at 37°C prior to inoculation onto 1.5 - 2 x 10 H9 cells in 5 ml RPMI 1640 supplemented fetal calf serum (2( HEPES (lOmM), penicillin (250 U/ml), streptomycin (250 μg/ml) and L-glutamine (2mM) . On days 5, 6, 7, 10 and 14, we examined each culture for characteris- ic cytopathic effects ("CPE"). Neutralization was defined as the inhibition of syncytia formation com- ared with controls. The positive control used was HIV seroposi- tive neutralizing serum, as described in D. D. Ho et al., "Human Immunodeficiency Virus Neutralizing Antibodies Recognize Several Conserved Domains On The Envelope Glycoproteins", J. Virol., 61, pp. 2024-28 (1987). The negative controls used were HIV seronegative serum only and buffer only. Cytopathic Effect Assay (CPE) In this assay, following conventional protocols for cytopathic effect assays [Klatzmann et al. (1984), supra and Wong-Staal and Gallo (1985), supra], we microscopically examined the H9 cells for evidence of cytopathic effects of HIV. The CPE was scored on a four point scale from 1+ to 4+, with 4+ representing the highest degree of CPE. By day 14, wells containing recombinant soluble T4 according to this invention (rsT4.2, derived from the pBG380 transfected CHO cell line BG380) at 10 μg/ml showed no evidence of CPE, while the negative control showed 1+ to 3+ CPE. p24 Radioimmunoassay We then tested soluble T4 as an inhibitor of viral replication in an HIV virus replication assay according to D. D. Ho et al., J. Virol., 61, pp. 2024-28 (1987) and J. Sodroski et al., Nature, 322, pp. 470-74 (1986). We carried out the assay essentially as described, except that the cultures were propagated in microtiter wells containing 200 μl. In this assay, we evaluated the ability of the soluble T4 polypeptides of this invention to block HIV replication, as measured by HIV p24 antigen production. We sampled supernatants twice weekly for HIV p24 antigen as described below. We obtained an assay kit [HTLV-III p24 Radioimmunoassay System, Catalogue No. NEK-040, NEK-040A, Biotechnology Systems, New Research Products, Dupont] which contains affinity purified 195I labelled HIV p24 anti.gen, a rabbi.t antι.-p24 antibody and a second goat anti-rabbit antibody which is used to precipitate antigen-antibody complexes. We carried out the assay according to the protocol included with the kit. Accordingly, we mixed a sample to be assayed or one of a series of amounts of unlabelled p24 antigen with a fixed amount of 125I labelled p24 and a fixed limited amount of rabbit anti-p24 antibody. We incubated the samples over¬ night at room temperature and then added a goat anti-rabbit immunoglobulin preparation for 5 minutes at 40°C. We centrifuged the samples in a microfuge and aspirated the supernatant fluid. Pelletted 125I labelled p24 was quantitated for each sample by gamma counting and a standard curve for the 125I p24 dis- placed by the known amounts of antigen added to standard tubes was constructed. We then calculated the 125I labelled p24 displaced by the antigen present in the unknown samples by interpolation using the standard curve constructed from the known amounts of p24 antigen contained in the standard samples. The results are shown in the table below. 24 ASSAY OF HIV REPLICATION INHIBITION Day 10 14 These results demonstrate that soluble T4 according to this invention at a concentration of 5 μg/ml completely inhibits virus replication as measured in this standard 14 day assay. These results are also depicted in Figure 39 in graphic form. In Figure 39, values were calculated from a standard curve of p24 according to assay kit instructions. * This concentration was initially believed to be 1.0 μg/ml, based upon our preliminary approximation that 1 unit of absorbance at 280 nm (" A 28θ "^' ' was equivalent to 1 mg of rsT4.2. Absorbance at 280 nm is a commonly used first approximation of protein concentration. Upon amino acid analysis of the pro¬ tein, however, we found that it had a higher extinc¬ tion coefficient than originally approximated, with 1 A 280 unit of rsT4.2 being equivalent to 0.5 mg of the protein. ** This concentration was initially believed to be 10 μg/ml, based upon our preliminary approximation that 1 unit of absorbance at 280 nm ("A 2ao "), was equivalent to 1 mg of rsT4.2. Absorbance at 280 nm is a commonly used first approximation of protein concentration. Upon amino acid analysis of the pro¬ tein, however, we found that it had a higher extinc¬ tion coefficient than originally approximated, with 1 A 2g0 unit of rsT4.2 being equivalent to 0.5 mg of the protein. We then carried out a p24 replication assay as described above, except that the soluble T4 was added to the infected cultures during refeeding at days 3, 7 and 10, in order to maintain a constant rsT4 concentration throughout the infection period. The results of this assay are shown in the table below. INHIBITION OF HIV REPLICATION WITH CONSTANT CONCENTRATION OF rsT4 rsT4.2 p24 (μq/ml) (nq/ml) 0.008 770 0.031 970 0.125 85 0.5 0 5.0 0 0 1120 uninfected 0 These results demonstrate that when solu- ble T4 protein according to this invention was main¬ tained at a constant concentration throughout the infection period, as little as 0.125 μg/ml of the protein substantially blocked replication of 250 TCID 50 /ml of HIV-1. Advantageously, soluble T4 protein accord¬ ing to this invention, at concentrations far exceed¬ ing those required to block viral replication, did not exert immunotoxic effects in vitro, as measured by three lymphocyte proliferation assays — mixed lymphocyte response, phytohemagglutinin, and tetanus toxoid stimulated response. Syncytia Inhibition Assay To further assess the effect of soluble T4 on HIV env-T4 binding, we evaluated the effect of two preparations of our soluble T4 protein on the syn- cytiagenic properties of HIV in the co-cultivation assay. We carried out a C8166 cell fusion assay as described in B. D. Walker et al., Proc. Natl. Acad. Sci. USA, 84, pp. 8120-24 (1984). g We incubated 1 x 10 H9 cells chronically infected with ΞTLV-IIIB for 1 hour at 37°C in 5% C0 2 with various concentrations of one of two preparations of rsT4.2 in 150 μl RPMI-1640 media supplemented with 20% fetal calf serum. We then added 3 x 10 4 C8166 cells m. 50 μl media (a T4+ transformed human umbilical cord blood lymphocyte line [Sodroski et al., supra] , to a final volume of 0.2 ml in each well. Final well concentrations of soluble T4 were 0.5 μg/ml* and 5.0 μg/ml* for prepa¬ ration #1 and 1.25 μg/ml* and 12.5 μg/ml* for prepa¬ ration #2. We then counted total number of syncytia per well at 2 hours and 4 hours after adding the C8166 cells at 37°C in 5% CC . Parallel co-cultiva¬ tions used buffer alone (negative control) or OKT4A at 25 μg/ml (positive control) as controls. We con¬ sidered a positive result as a 50% reduction in syncytia compared to controls, at a time when at least 100 syncytia per 10 4 infected H9 cells were present in the control cultivations. The results of this assay are shown below and in Figure 40 (2 hour data) . * These concentrations were initially believed to be, respectively, 1 μg/ml, 10 μg/ml, 2.5 μg/ml and 25 μg/ml, based upon our preliminary approxima¬ tion that 1 unit of absorbance at 280 nm ("A 2ao "), was equivalent to 1 mg of rsT4.2. Upon amino acid analysis of the protein, however, we found that it had a higher extinction coefficient than originally approximated, with 1 A 2aQ unit of rsT4.2 being equivalent to 0.5 mg of rhe protein. INHIBITION IN C8166 FUSION ASSAY As demonstrated in this table and in Fig¬ ure 40, soluble T4 according to this invention at 5.0 μg/ml and 12.5 μg/ml inhibited syncytia formation at 2 hours, as compared to buffer alone. By 4 hours after the addition of C8166 cells, soluble T4 at 12.5 μg/ml continued to inhibit greater than 50% syncytia formation, as compared to the negative control. We also evaluated the effect of two prep¬ arations of our soluble T4 protein rsT4.7 on the syncytiagenic properties of HIV in a similar co- cultivation assay. The results of this assay are shown below. * All assays were carried out in triplicate, and the number of syncytia counted per well was averaged to calculate % inhibition. The % inhibition repre¬ sents the difference between the average number of syncytia in the negative control (without rsT4 or 0KT4A) and the average number of syncytia counted when either rsT4 or 0KT4A were present during the assay, divided by the average syncytia count for the negative control and multiplied by 100. - ** These concentrations were initially believed to be, respectively, 1 μg/ml, 10 μg/ml, 2.5 μg/ml and 25 μg/ml, based upon our preliminary approxima¬ tion that 1 unit of absorbance at 280 nm ("A 2ao "), was equivalent to 1 mg of rsT4.2. Upon amino acid analysis of the protein however, we found that it had a higher extinction coefficient than originally approximated, with 1 A, aQ unit of rsT4.2 being equivalent to 0.5 mg or the protein. INHIBITION IN C8166 FUSION ASSAY * This concentration '/as initially believed to be 10 μg/ml, based upon our preliminary approxima¬ tion that 1 unit of absorbance at was equivalent to 1 mg of rsT4.2. analysis of the protein, however, had a higher extinction coefficient than originally approximated, with 1 A_ ao unit of rsT4.2 being equivalent to 0.5 mg o the protein. date : dav 13 Preparation H9 cells (control) C8166 cells (control) HIV-infected 0 141 0 H9 cells added to C8166 cells (control) 0KT4A (control) 0 0 . 100 Prep. 2 of rsT4.7 ≤ 5.0* 27 80.9 * This concentration was initially believed to be 10 μg/ml, based upon our preliminary approxima¬ tion that 1 unit of absorbance at 280 nm ("A_ ''), was equivalent to 1 mg of rsT4.2. Upon amino acid analysis of the protein, however, we found that it had a higher extinction coefficient than originally approximated, with 1 A 2aQ unit of rsT4.2 being equivalent to 0.5 mg of the protein. Assa y da e; day.14. Average rsT4.7 Syncytia/50μl % Inhibition Preparation (μg/ml) aliquot at 2 Hrs H9 cells N/A (control) C8166 cells 0 N/A (control) HIV-infected 128 H9 cells added C8166 cells (control) 0KT4A (control) 100 Prep. 1 of rsT4.7 ≥ 5.0* 35 72.7 Prep. 2 of rsT4.7 S 5.0* 98.4 As demonstrated in these tables, soluble T4 protein rsT4.7 inhibited syncytia formation in HIV-infected H9 cells. We also evaluated the effect of rsT4.113.1 and rsT4.111 on the syncytiagenic properties of HIV in a co-cultivation assay. We carried out a C8166 cell fusion assay as described in Walker et al. , supra. We incubated 1 x 10 4 H9 cells chronically infected with HTLV-IIIB for 1 hour at 37°C in 5% C0 2 , with from 5 to 50 μg/ml rsT4.113.1 or rsT4.111 in 150 μl RPMI-1640 media supplemented with 20% fetal calf serum in 96-well microtiter plates. We * This concentration was initially believed to be 10 μg/ml, based upon our preliminary approxima¬ tion that 1 unit of absorbance at 280 nm ("A^ o "), was equivalent to 1 mg of rsT4.2. Upon amino acid analysis of the protein, however, we found that it had a higher extinction coefficient than originally approximated, with 1 A 28Q unit of rsT4.2 being equivalent to 0.5 mg of the protein. then added 3 x IO 4 C8166 cells to the wells in 50 μl aliquots. The plates were incubated for 2 hours at 37°C in 5% CO, and, following this incubation, the number of syncytia per well were counted. Syncytia were defined as cells containing a ballooning cytoplasm greater than three cell diameters. All samples were counted twice. Parallel co-cultivation used 0KT4A alone or rsT4.3 alone at a concentration of 25 μg/ml (positive controls) or H9 cells alone or C8166 cells alone (negative controls). The results of this assay are shown below and in Figure 41. INHIBITION IN C8166 FUSION ASSAY As demonstrated in this table and in Figure 41, rsT4.113.1 exhibited a dose-dependent inhibition of HIV-induced syncytia formation. The molar specific inhibitory activity of rsT4.113.1 appeared to be reduced by an order of magnitude by comparison to anti-viral activity of longer forms of recombinant soluble T4. Thus, whereas rsT4.113.1 is effective toward neutralization of HIV-dependent cell fusion in vitro, its molar specific inhibitory activity is decreased by a factor of 10. It is undetermined whether this decreased potency is due to incomplete renaturation of the E.coli-derived protein, the presence of three additional amino acids at the N-terminus of rsT4.113.1 (Met-Gln-Gly) lacking in rsT4.2 or rsT4.3 produced in mammalian cells, or the absence of additional structure in rsT4.113.1 required for high-affinity binding to HIV. We also carried out a C8166 cell fusion assay with rsT4.111, as described for rsT4.113.1. The results of this assay are shown below. INHIBITION IN C8166 FUSION ASSAY As demonstrated in this table, rsT4.111 exhibited a dose-dependent inhibition of HIV-induced syncytia formation. At a concentration of 12.5 μg/ml and 25.0 μg/ml, complete inhibition of cell fusion was achieved. Kinetics Of Intramuscular Injection Of Soluble T4 We examined the kinetics of the appearance of a recombinant soluble T4 protein according to this invention (specifically, rsT4.3 from the pBG381- transfected cell line BG381) in serum after intra¬ muscular injection as follows. We obtained two cynomolgus monkeys (Macaca fascicularis) who were free of infectious disease and in good health. Each monkey had been subjected to a 6 week quarantine period prior to administration of the soluble T4 protein. Throughout the adminis¬ tration period, each monkey was maintained on a con¬ ventional diet of monkey chow supplemented with fresh fruit. A catheter and a vascular access port were surgically placed in a femoral vein of each animal prior to treatment in order to facilitate blood collection. Over a period of 28 days, each animal received recombinant soluble T4 protein twice daily by intramuscular injection to the large muscles of the thighs or buttocks. Injections were administered to each animal 8 hours apart and each injection con¬ tained a volume of 0.15 ml/kg (0.25 mg/kg) of rsT4.3 (from the pBG381-transformed cell line BG381), for a total dose of 0.5 mg/kg/day/monkey. Serum samples for clearance determination were collected on day 1 before the first treatment and at 1, 2, 4 and 8 hours after the first injection, as well as 1, 2 , 4, 14 and 16 hours after the second injection on days 7, 14 and 28. We found that intramuscularly injected soluble T4 reached the maximum level in serum between 1 and 2 hours after injection, with the level falling off slowly and reaching half-maximum value at approxi¬ mately 6 hours post-injection. According to data obtained for intravenous administration (not shown), the level of rsT4.3 in serum should drop below that attained via intramuscular injection aproximately 2 hours after intravenous injection. Thus, while the maximum rsT4.3 level in serum after intramuscular injection does not reach that attainable via intra¬ venous injection, it is slowly released into the blood stream, remaining detectable in serum for a much longer time. This slow release mechanism asso¬ ciated with intramuscular routes of injection is advantageous because a higher level of soluble T4 protein is available over a longer period of time over a given concentration; thus remaining in a sus¬ tained level. Intramuscular administration of solu¬ ble T4 protein is particularly useful in treating early stage HIV-infected patients, to prevent the virus from disseminating, or in treating patients who have been exposed to the virus and who are not yet seropositiv . We determined serum levels of rsT4.3 using an ELISA assay. Throughout this assay, dilutions were made in blocking solution and, between each step, we washed the plates with PBS/0.05% Tween-20. More specifically, we coated wells of Immulon 2 plates with .01 OD (280 nm)/ml of 0KT4 (IgG2b) in 0.05 M bicarbonate buffer to a volume of 50 μl/well and incubated the plates overnight at 4°C. We then blocked the plates with 5% bovine serum albumin in PBS, 200 μl/well, and incubated for 30 minutes at room temperature. Subsequently, we added 50 μl of sample or standard to each well, incubating for 4 hours at room temperature. We then added 50 μl/well of 0KT4A at 0.1 μg/ml and incubated overnight at 4°C. Using a Hyclone Kit (Hyclone) we then carried out the fol¬ lowing steps. First, we added 1 drop of rabbit anti-mouse IgG2a to each well and incubated the plates for 1 hour at room temperature. We then added 100 μl of peroxidase-labeled anti-rabbit IgG, diluted 1:4000 with 5% BSA/PBS to each well, and incubated for 1 hour at room temperature. We prepared a substrate reagent as follows. We diluted substrate reagent 1:10 in distilled water and added two O-phenyl-ethylene-diamine ("OPD") chromophore tablets per 10 ml of substrate. We let the mixture dissolve thoroughly by mixing with a vortex. Alternatively, a TMB peroxidase substrate system (Kirkegaard & Perry Catalogue #50-76-00) may be used. Subsequently, we added 100 μl of the chromophore solution to each well, incubated for 10-15 minutes at room temperature and then stopped the color development with 100 μl of IN H 2 S0 4 - We then measured OD at 490 nm, using an ELISA plate reader. The results of the assay are demonstrated in the tables below. Monkey #7-91 - background ** - second injection administered after the collection of the 8 hour sample. Polyvalent Forms Of Recombinant Soluble T4 Receptors may be characterized by their affinity for specific ligands, such that, at equili¬ brium, the intrinsic affinity (Kcl) between monovalent receptor and monovalent ligand can be defined as [RL]/[R f ] [L f ] , where [RL] is the concentration of receptor (R) bound to ligand (L) and [R f ] and [L f ] are the concentrations of free receptor and ligand, respectively [P. A. Underwood, in Advances In Virus Research, ed. K. Maramorosch et al., 34, pp. 283-309 (1988)]. For a polyvalent receptor (with a valency of n) binding to a polyvalent ligand (with a valency of m), a functional affinity can be defined as n[R v .]/n[R f ]m[L f ], where [R, ] is the concentration of bound receptor sites, and n[R f ] and m[L f ] are, respec¬ tively, the concentrations of free receptor and ligand binding sites. The effect of increasing the valence (the number of binding sites) is to enhance the stability of ligand-receptor complexes. The affinity of a polyvalent receptor for a polyvalent ligand will depend on three factors: the intrinsic association constant of each binding site, the valency (number of binding sites) and the topico- logical relationship between the receptor and ligand binding sites. Under some circumstances, polyvalent binding interactions will lead to higher functional affinity. The decreased dissociation rate of poly¬ valent ligands with polyvalent receptors results in an increased functional affinity [C. L. Hornick and F. Karush, Immunochemis ry, 9, pp. 325-40 (1972); I. Otterness and F. Karush, "Principles Of Antibody Reactions", in Antibody As A Tool, ed. J. J. Marchalonais and G.W. Warr, pp. 97-137 (1982)]. The simplest case for receptor polyvalency increasing functional affinity is represented by a bivalent soluble receptor, such as an antibody molecule, which has two identical ligand binding sites, each capable of independently binding antigen with equal affinity. If the antigen is displayed polyvalently, for example, chemically coupled to a solid support such that the spacing between antigenic sites can be bridged by the antibody's two antigen binding arms, the functional affinity of the antibody for the antigen coupled to the solid support would be greater than the intrinsic affinity of the antibody binding site for the monovalent antigen [D. Crothers and H. Metzger, Immunochemistry, 9, pp. 341-57 (1972)]. Because virus particles represent poly- - valent antigens, the greater functional affinity of antibodies for polyvalent antigens is an important factor for antibody-directed virus neutralization. The association of recombinant soluble T4 and the HIV major envelope glycoprotein gpl20 is an example of monovalent receptor binding to monovalent ligand. The affinity of this interaction has been measured, and the association between T4 and gpl20 has a dissociation constant K. = 4 x 10 -9 M [L. Lasky et al., Cell, 50, pp. 975-88 (1987)]. ' Using the antibody analogy, we believe that polyvalent rsT4 will demonstrate a greater affinity for HIV-infected cells displaying gpl20 than monovalent rsT4 and the topicological relation¬ ship between gpl20 on the virus particle or the infected cell surface, will determine the degree to which polyvalent rsT4 exhibits higher functional affinity than monovalent rsT4. One example of a polyvalent rsT4 is described below, with respect to the production of a recombinant bivalent rsT4 con- sisting of two tandem repeats of amino acids 3-178, followed by the C-terminal 199 amino acids of rsT4.3. According to this invention, a "polyvalent" receptor possesses two or more binding sites for a given ligand. Furthermore, the intrinsic affinity of each ligand binding site of a given polyvalent receptor need not be identical. As shown in Figure 42, to construct bivalent rsT4, we digested pBG391 with Nhel, which cleaves after the valine at position 178 in rsT4, and removed the Nhel 5' overhang with mung bean nuclease. Next, we cleaved with Bglll to remove the C-terminal half of the rsT4 coding sequence in pBG391. Finally, we ligated a Dral-Bglll fragment containing the coding sequence for rsT4 amino acids 3 (lysine) through 377 (isoleucine) to the cleaved pBG391 to create pBiv.l, a plasmid coding for a fusion protein with a tandem duplication of the N-terminal 176 amino acids of rsT4, followed by the C-terminal 199 amino acids of rsT4.3. The protein produced by this plasmid, therefore, contains two adjacent N-terminal gpl20- binding or 0KT4A-binding domains (defined by amino acid residues 3 through 111 of rsT4.111), followed by one 0KT4-binding C-terminal domain (Figure 43). pBiv.l was transfected by electroporation into COS 7 cells to test expression of the bivalent rsT4 protein. Three days later, we tested the con- ditioned medium of the transfected cells for the presence of the rsT4 bivalent protein by immuno¬ precipitation, followed by Western blot analysis of the precipitated protein. Both 0KT4A and 0KT4 were used for immuno-precipitation to determine that the 0KT4 epitope and at least one of the 0KT4A epitopes had folded correctly. Both antibodies precipitated a protein of the predicted apparent molecular weight (60,000d) from the conditioned medium of the cells. Bivalent rsT4 may be purified by immuno- affinity purification from an 0KT4 column and the purified protein may then be used to perform quanti¬ tative competition assays with rsT4.3. We believe that the bivalent molecule would demonstrate equi¬ valent competition against rsT4.3 for 0KT4 binding, but significantly greater competition against mono¬ valent rsT4 for 0KT4A binding. The ability of bivalent recombinant soluble T4 to block syncytium formation may also be demonstrated in the C8166 fusion assay. We also believe that bivalent recombinant soluble T4 would block syncytium formation at significantly lower concentrations than monovalent rsT4; based upon the higher functional affinity of bivalent recombinant soluble T4 for gpl20. According to alternate embodiments of this invention, other methods for producing polyvalent rsT4 may be employed. For example, polyvalent rsT4 may be produced by chemically coupling rsT4 to any clinically acceptable carrier molecule, a polymer selected from the group consisting of Ficoll, poly¬ ethylene glycol or dextran, using conventional coupling techniques. Alternatively, rsT4 may be chemically coupled to biotin, and the biotin-rsT4 conjugate then allowed to bind to avidin, resulting in tetravalent avidin/biotin/rsT4 molecules. And rsT4 may be covalently coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and the resulting conjugate precipitated with anti-DNP or anti-TNP- Igm, to form decameric conjugates with a valency of 10 for rsT4 binding sites. Alternatively, a recombinant chimeric antibody molecule with rsT4 sequences substituted for the variable domains of either or both of the immunoglobulin molecule heavy and light chains may be produced. Because recombinant soluble T4 possesses gpl20 binding activity, the construction of a chimeric antibody having two soluble T4 domains and having unmodified constant region domains could serve as a mediator of targeted killing of HIV- infected cells that express gpl20. For example, chimeric rsT4/IgG-, may be produced from two chimeric genes — an rsT4/human kappa light chain chimera (rsT4/C, aDDa ) and an rsT4/human gamma 1 heavy chain chimera (rsT4/Cga a m ιm m n a_- η l) . Both C,Jc„ap„pa a and Cg„a = m ττι m m a a -l- regions have been isolated from human libraries, and each has been subcloned into animal cell selection vectors containing either the bacterial neo resistance or bacterial gpt markers for selection in animal cell hosts against the antibiotic G418 or mycophenolic acid, respectively. To construct rsT4/Cga.,mma,-.l. and rsT4/C,ka„ppa, chimeric genes, an rsT4 gene segment, including at least the secretory signal sequence and the N-terminal 110 amino acid residues of the mature rsT4 coding sequence and including a splice donor or portion thereof, is placed upstream of the gamma-l and kappa constant domain exons. A suitable restriction enzyme may be used to cut within the intron down¬ stream of the desired rsT4 coding sequence, thus providing a donor splice site. Subsequently, a suitable restriction enzyme is used to cut within the introns upstream of the kappa and gamma-l coding regions. The rsT4 sequence is then joined to the kappa or gamma-l constant region sequence, such that the rsT4 intron sequence is contiguous with the gamma-l and kappa introns. In this way, an acceptor splice site is provided by the kappa or gamma-l constant region intron. Alternatively, rsT4 chimeric genes may be constructed without the use of introns, by fusing a suitable rsT4 cDNA gene segment directly to the gamma-l or kappa coding regions. The rsT4/Cg „a ^ ,m rn m m a ^ - -l, and rsT4/C,ka,p„p,a., vectors may then be cotransfected, for example, by electro¬ poration into lymphoid or non-lymphoid host cells. Following transcription and translation of the two chimeric genes, the gene products may assemble into chimeric antibody molecules. Expression of the chimeric gene products may be measured by an enzyme-linked immunoadsorbant assay (ELISA) that utilizes monoclonal anti-T4 anti¬ body 0KT4A, as described infra, or in gpl20 competi¬ tion assays and radioimmunoassays, as described infra. Activity of the rsT4/IgG-. chimeras may be measured by incubating them with HIV-infected cells in the presence of human complement, followed by quantitating subsequent complement-mediated lysis of these cells. Alternatively, activity may be measured in HIV repli¬ cation and HIV syncytium assays as described infra. In order to determine if bivalent rsT4 has a greater potency than monovalent rsT4, we mixed 0KT4, at various concentrations, together with a constant concentration of rsT4, so that the molar ratio of 0KT4:rsT4 varied between 0.2 and 4. After preincubating the mixture overnight at 4°C, we added aliquots to the HIV syncytium assay described infra. 0KT4 has no observable effect in this assay when used alone. In addition, the concentration of recombinant soluble T4 chosen did not cause inhibition in this assay. Accordingly, we looked for indications that the 0KT4/rsT4 mixture was more potent than rsT4 alone. We observed that at ratios of 0KT4:rsT4 greater than 0.2, partial to complete inhibition of syncytium formation occurred. We believe that under conditions where two rsT4 molecules are bound to 1 0KT4 molecule, the greatest inhibitory effect should be found. Thus, polyvalent, as well as monovalent forms of recombinant soluble T4 are useful in the compositions and methods of this invention. Microorganisms and recombinant DNA mole- cules prepared by the processes of this invention are exemplified by cultures deposited in the In Vitro International, Inc. culture collection, in Linthicum, Maryland, on September 2, 1987, and identified as: BG378 E.coli MC1061/pBG378 199-7 E.coli MC1061/pl99-7 170-2 E.coli JA221/pl70-2 EC100 E.coli JM83/pEC100 BG377 E.coli MC1061/pBG377 BG380 E.coli MC1061/pBG380 BG381 E.coli MC1061/pBG381 These cultures were assigned accession numbers IVI 10143-10149, respectively. In addition, microorganisms and recombinant DNA molecules according to this invention are exempli¬ fied by cultures deposited in the In Vitro Interna¬ tional, Inc. culture collection, in Linthicum, Maryland, on January 6, 1988, and identified as: BG-391 E.coli MC1061/pBG391 BG-392 E.coli MC1061/pBG392 BG-393 E.coli MC1061/pBG393 BG-394 E.coli MC1061/pBG394 BG-396 E.coli MC1061/pBG396 203-5 E.coli SG936/p203-5. These cultures were assigned accession numbers IVI 10151-10156, respectively. Microorganisms and recombinant DNA mole- cules according to this invention are also exempli¬ fied by cultures deposited in the In Vitro International, Inc. culture collection, in Linthicum, Maryland, on August 24, 1988 and identified as: 211-11: E.coli A89/pBG211-ll 214-10: E.coli A89/pBG214-10 215-7 : E.coli A89/pBG215-7 These cultures were assigned accession numbers IVI 10183-10185 respectively. While we have hereinbefore described a number of embodiments of this invention, it is apparent that our basic constructions can be altered to provide othe embodiments which utilize the pro¬ cesses and compositions of this invention. There¬ fore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than by the specific embodiments which have been presented hereinbefore by way of example.

Claims: CLAIMS We claim: 1. A DNA sequence selected from the group consisting of: (a) the DNA inserts of pl99-7, pBG377, pBG380, pBG381, p203-5, pBG391, pBG392, pBG393, pBG394, pBG395, pBG396, pBG397, p211-ll, p214-10 and p215-7; (b) DNA sequences which hybridize to one or more of the foregoing DNA inserts and which code on expression for a soluble T4-like polypeptide; and (c) DNA sequences which code on expression for a soluble T4-like polypeptide coded for on expression by any of the foregoing DNA inserts and sequences. 2. The DNA sequence according to claim 1, wherein said DNA sequence (b) codes on expression for a soluble T4-like polypeptide which inhibits adhesion between T4 lymphocytes and infective agents which target T4 lymphocytes and which inhibits interaction between T4 lymphocytes and antigen pre¬ senting cells and targets of T4 lymphocyte mediated killing. 3. A recombinant DNA molecule comprising a DNA sequence selected from the group consisting of the DNA sequences of claim 1 or 2, said DNA sequence being operatively linked to an expression control sequence in said recombinant DNA molecule. 4. The recombinant DNA molecule according to claim 3, wherein said expression control sequence is selected from the group consisting of the early or late promoters of SV40 or adenovirus, the lac system, the trp system, the TAC system, the TRC . system, the major operator and promoter regions of phage λ, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the promoters of acid phosphatase, the polyhedron promoter of the baculovirus system and the promoters of the yeast α-mating factors. 5. A unicellular host transformed with a recombinant DNA molecule selected from the group consisting of the recombinant DNA molecules of claim 3 or 4. 6. The host according to claim 5, wherein said host is selected from the group consisting of strains of E.coli, Pseudomonas, Bacillus, Streptomyces, fungi, animal cells, plant cells, insect cells and human cells in tissue culture. 7. A polypeptide coded for on expression by a DNA sequence selected from the group consisting of the DNA sequences of claim 1 or 2, said polypep¬ tide being essentially free of other proteins of human origin. 8. The polypeptide according to claim 7, wherein said polypeptide is selected from the group consisting of a polypeptide of the formula AA_ 23 -AA 362 of Figure 3, a polypeptide of the formula AA-t ? °^ Figure 3, a polypeptide of the formula Met-AA,_ 362 of Figure 3, a polypeptide of the formula AA τ _ 74 °f Figure 3, a polypeptide of the formula Met-AA.,_ 374 of Figure 3, a polypeptide of the formula AA, 377 of Figure 3, a polypeptide of the formula Met-AA,_ 37 _ of Figure 3, a polypeptide of the formula AA_ 23 -AA 374 of Figure 3, a polypeptide of the formula AA_ >23 ~AA 37 - of Figure 3. 9. The polypeptide according to claim 7, wherein said polypeptide is selected from the group consisting of a polypeptide of the formula AA_ 23 -AA, 82 of Figure 16, a polypeptide of the formula AA,-AA, g2 of Figure 16, a polypeptide of the formula Met-AA, , a2 of Figure 16, a polypeptide of the formula AA_ 23 -AA, g2 of Figure 16, followed by the amino acids asparagine-leucine-glutamine- histidine-serine-leucine, a polypeptide of the formula AA,-AA ιa2 of Figure 16, followed by the amino acids asparagine-leucine-glutamine-histidine-serine-leucine, a polypeptide of the formula Met-AA, , a2 of Figure 16, followed by the amino acids asparagine-leucine- glutamine-histidine-serine-leucine, a polypeptide of the formula AA _23~ AA 113 of F--'3 x -- ce 16 ' a polypeptide of the formula AA,-AA,, 3 of Figure 16, a polypeptide of the formula Met-AA, 113 of Figure 16, a polypeptide of the formula AA „2 3 '" AA 111 °^ F i5u re 16 ' a polypeptide of the formula AA T 'AAH I °f Figure 16, a polypeptide of the formula Met-AA, ,,, of Figure 16, a polypep¬ tide of the formula AA_ 23 -AA, 3 , of Figure 16, a poly¬ peptide of the formula AA-.-AA,.,, of Figure 16, a polypeptide of the formula Met-AA, ,.,, of Figure 16, a polypeptide of the formula AA_ 23 -AA, 45 of Figure 16, a polypeptide of the formula AA,-AA, 45 of Figure 16, a polypeptide of the formula Met-AA, , 4ς of Figure 16, a polypeptide of the formula AA_ 23 -AA, g6 of Figure 16, a polypeptide of the formula AA,-AA, 66 of Figure 16, a polypeptide of the formula Met-AA,_ 166 of Figure 16, or portions thereof. 10. The polypeptide according to claim 7, wherein said polypeptide is selected from the group consisting of a polypeptide of the formula AA_ 23 -AA 362 of mature T4 protein, a polypeptide of the formula AA.._,.,„ of mature T4 protein, a polypeptide of the formula Met-AA,_ 362 of mature T4 protein, a polypep- tide of the formula ._ 374 of mature T4 protein, a polypeptide of the formula Met-AA.._ 374 of mature T4 protein, a polypeptide of the formula AA,_ 377 of mature T4 protein, a polypeptide of the formula Met-AA, 377 of mature T4 protein, a polypeptide of the formula AA_ 23 -A 374 of mature T4 protein, a poly¬ peptide of the formula AA_ 23 -AA 377 of mature T4 pro¬ tein, or portions thereof. 11. The polypeptide according to claim 7, wherein said polypeptide is selected from the group consisting of a polypeptide of the formula AA_ 23 -AA-. g2 of mature T4 protein, a polypeptide of the formula AA,-AA lg2 of mature T4 protein, a polypeptide of the formula Met-AA, lg2 of mature T4 protein, a polypep- tide of the formula AA_ 23 -AA, g2 of mature T4 protein, followed by the amino acids asparagine-leucine- glutamine-histidine-serine-leucine, a polypeptide of the formula AA,-AA, g2 of mature T4 protein, followed by the amino acids asparagine-leucine-glutamine- histidine-serine-leucine, a polypeptide of the formula Met-AA, lg2 of mature T4 protein, followed by the amino acids asparagine-leucine-glutamine-histidine- serine-leucine, a polypeptide of the formula AA_ 23 -AA,, 3 of mature T4 protein, a polypeptide of the formula AA-,-AA,, 3 of mature T4 protein, a polypep¬ tide of the formula Met-AA, , 13 of mature T4 protein, a polypeptide of the formula AA_ 23 -AA 11 , of mature T4 protein, a polypeptide of the formula AA,-AA,,, of mature T4 protein, a polypeptide of the formula Met-AA 1 _ 111 of mature T4 protein, a polypeptide of the formula AA_ 23 -AA, 31 of mature T4 protein, a poly¬ peptide of the formula AA-,-AA-, 31 of mature T4 protein, a polypeptide of the formula Met-AA.,_ 131 °f mature T4 protein, a polypeptide of the formula AA__ 3 -AA-, 4C - of mature T4 protein, a polypeptide of the formula AA.,-AA, 4 _ of mature T4 protein, a polypeptide of the formula Met-AA, 145 of mature T4 protein, a polypep¬ tide of the formula of mature T4 protein, a polypeptide of the formula AA,-AA 16fi of mature T4 protein, a polypeptide of the formula Met-AA, , 66 of mature T4 protein, or portions thereof. 12. A method for producing a polypeptide selected from the group consisting of the polypeptides of any one of claims 7 to 11 comprising the step of culturing a unicellular host transformed with a recom- binant DNA molecule selected from the group consisting of the recombinant DNA molecules of claim 3 or 4. 13. A pharmaceutical composition comprising an immunotherapeutic or immunosuppressive effective amount of a polypeptide selected from the group con- sisting of the polypeptides of any one of claims 7 to 11 and a pharmaceutically acceptable carrier. 14. A method for treating patients com¬ prising the step of treating them in a pharmaceuti¬ cally acceptable manner with a composition selected from the group consisting of the composition of claim 13. 15. The method according to claim 14, wherein the patient is treated by intramuscular injection of the composition. 16. A diagnostic composition for detecting or for monitoring the course of HIV infection com¬ prising a diagnostic effective amount of a polypeptide selected from the group consisting of the polypeptides of any one of claims 7 to 11. 17. A method for detecting or for moni¬ toring the course of HIV infection comprising the step of employing as a diagnostic a composition selected from the group consisting of the compositions of claim 16. 18. A means for detecting or for monitoring the course of HIV infection comprising a composition selected from the group consisting of the compositions of claim 16. 19. A pharmaceutical composition compris¬ ing an immunotherapeutic or im unosuppressive effec- tive amount of antibody to a polypeptide selected from the group consisting of the polypeptides of any one of claims 7 to 11 and a pharmaceutically accept¬ able carrier. 20. A method for treating patients com- prising the step of treating them in a pharmaceuti¬ cally acceptable manner with a composition according to claim 19. 21. The use of a polypeptide selected from the group consisting of the polypeptides of any one of claims 7 to 11 to purify HIV virus. 22. The use according to claim 20, wherein the HIV virus is purified from a biological sample. 23. A method for purifying HIV virus from a sample comprising the step of exposing the sample to a polypeptide selected from the group consisting of the polypeptides of any one of claims 7 to 11. 24. The method according to claim 22, wherein the sample is a biological sample.. 25. A DNA sequence comprising the DNA insert of pl70-2, said sequence coding on expression for a T4-like polypeptide. 26. A recombinant DNA molecule comprising 5 a DNA sequence selected from the group consisting of the DNA sequence of claim 25, said DNA sequence being operatively linked to an expression control sequence in said recombinant DNA molecule. 27. A unicellular host transformed with a IΦ recombinant DNA molecule according to claim 26. 28. A polypeptide coded for on expression by a DNA sequence of claim 25, said polypeptide being essentially free of other proteins of human origin. 29. A pharmaceutical composition comprising 15 an immunotherapeutic or immunosuppressive amount of a soluble protein receptor and a pharmaceutically acceptable carrier. 30. A method for treating patients comprising the step of treating them in a pharma- 0 ceutically acceptable manner with a pharmaceutical composition of claim 29. 31. A diagnostic composition for detecting or for monitoring the course of viral infection com¬ prising a diagnostic effective amount of a soluble 5 protein receptor. 32. A method for detecting or for moni¬ toring the course of a viral infection comprising the step of employing as a diagnostic a diagnostic effective amount of a soluble protein receptor. 33. A means for detecting or for moni¬ toring the course of a viral infection comprising a soluble protein receptor. 34. A DNA sequence selected from the group consisting of: (a) the DNA insert of pBiv.l; (b) DNA sequences which hybridize to the DNA insert of pBiv.l and which code on expression for a polyvalent soluble T4-like polypeptide; and (c) DNA sequences which code on expression for a polyvalent soluble T4-like polypep¬ tide coded for by the DNA insert of pBiv.l. 35. A recombinant DNA molecule comprising a DNA sequence selected from the group consisting of the DNA sequences of claim 34, said DNA sequence being operatively linked to an expression control sequence in said recombinant DNA molecule. 36. A unicellular host transformed with a recombinant DNA molecule according to claim 35. 37. A polypeptide coded for on expression by a DNA sequence selected from the group consisting of the DNA sequences according to claim 34, said polypeptide being essentially free of other proteins of human origin. 38. The polypeptide according to claim 7, wherein said polypeptide is polyvalent. 39. A method for producing a polyvalent polypeptide comprising the steps of: (a) culturing a unicellular host transformed with a recombinant DNA molecule according to claim 3 or 4 to produce a polypeptide; and (b) coupling said polypeptide to a carrier to form a polyvalent polypeptide. 40. A DNA sequence comprising: (a) a first portion comprising a DNA sequence coding for the constant region of an immuno¬ globulin light chain; and (b) a second portion comprising a DNA sequence according to claim 1 or 2, or portions thereof, said second portion being joined upstream of said first portion. 41. A DNA sequence comprising: (a) a first portion comprising a DNA sequence coding for the constant region of an immuno¬ globulin heavy chain; and (b) a second portion comprising a DNA sequence according to claim 1 or 2, or portions thereof, said second portion being joined upstream of said first portion. 42. An expression vector comprising the DNA sequence according to claim 40. 43. An expression vector comprising the DNA sequence according to claim 41. 44. An expression vector comprising the DNA sequence according to claim 40 and the DNA sequence according to claim 41. 45. A method for producing a chimeric rsT4/IgG comprising the step of co-transfecting a host cell with the expression vector according to claim 42 and the expression vector according to claim 43. 46. A method for producing a chimeric rsT4/IgG 1 comprising the step of transfecting a host cell with the expression vector according to claim 44. 47. A chimeric rsT4/IgG, produced by the method according to claim 45 or 46. 48. A pharmaceutical composition comprising an immunotherapeutic or immunosuppressive effective amount of a polypeptide according to claim 37 or 38. 49. A method for treating patients com¬ prising the step of treating them in a pharmaceuti¬ cally acceptable manner with a composition according to claim 48. 50. A diagnostic composition for detecting or for monitoring the course of HIV infection com¬ prising a diagnostic effective amount of a polypeptide according to claim 37 or 38. 51. A pharmaceutical composition comprising an immunotherapeutic or immunosuppressive effective amount of a chimeric rsT4/IgG, according to claim 47. 52. A method for treating patients com¬ prising the step of treating them in a pharmaceuti¬ cally acceptable manner with a composition according to claim 51.

Inventors: FISHER RICHARD A, FLAVELL RICHARD A, GILBERT WALTER, LIU THERESA R, MARAGANORE JOHN M, SATO VICKI L, FISHER, RICHARD, A., FLAVELL, RICHARD, A., GILBERT, WALTER, LIU, THERESA, R., MARAGANORE, JOHN, M., SATO, VICKI, L.
Applicants: BIOGEN INC, BIOGEN, INC.
Application year: 1988
Main classification: C07H15
IPC codes: A61K38, A61K39, A61P37, C07K14, C07K16, C07K19, C12N1, C12N7, C12N15, C12P21, C12R1, G01N33